AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 109_CD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Assets_NNPS pledged_VBD Mortgages_NNS and_CC other_JJ assets_NNS pledged_VBD 90_CD Commitments_NNS Contracts_NNS placed_VBN for_IN future_JJ capital_NN expenditure_NN not_RB provided_VBN for_IN in_IN these_DT accounts_NNS 298 421 500_CD Included_VBN in_IN the_DT above_JJ total_NN are_VBP contracts_NNS related_VBN to_TO certain_JJ product_NN purchase_NN and_CC licence_NN agreements_NNS with_IN deferred_JJ consideration_NN obligations_NNS ,_, the_DT amounts_NNS of_IN which_WDT are_VBP variable_JJ depending_VBG upon_IN particular_JJ milestone_NN achievements_NNS ._.
Sales_NNS of_IN the_DT products_NNS to_TO which_WDT these_DT milestones_NNS relate_VBP could_MD give_VB rise_VB to_TO additional_JJ payments_NNS ,_, contingent_NN upon_IN the_DT sales_NNS levels_NNS achieved_VBN ._.
Guarantees_NNS and_CC contingencies_NNS arising_VBG in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, for_IN which_WDT no_DT security_NN has_VBZ been_VBN given_VBN ,_, are_VBP not_RB expected_VBN to_TO result_VB in_IN any_DT material_NN financial_JJ loss_NN ._.
Commitments_NNS In_IN 1982_CD Astra_NNP AB_NNP set_VBD up_RP a_DT joint_JJ venture_NN with_IN Merck_NNP &_CC Co._NNP ._.
Inc._NNP for_IN the_DT purposes_NNS of_IN selling_NN ,_, marketing_NN and_CC distributing_VBG certain_JJ Astra_NNP products_NNS in_IN the_DT US_NNP ._.
In_IN 1998_CD ,_, this_DT joint_JJ venture_NN was_VBD restructured_VBN the_DT restructuring_NN ._.
Under_IN the_DT restructuring_NN ,_, a_DT US_NNP limited_JJ partnership_NN ,_, in_IN which_WDT Merck_NNP is_VBZ the_DT limited_JJ partner_NN and_CC AstraZeneca_NNP is_VBZ the_DT general_JJ partner_NN ,_, was_VBD set_VBN up_RP and_CC AstraZeneca_NNP obtained_VBD control_NN of_IN the_DT joint_JJ ventures_NNS business_NN subject_NN to_TO certain_JJ limited_JJ partner_NN and_CC other_JJ rights_NNS held_VBN by_IN Merck_NNP and_CC its_PRP$ affiliates_NNS ._.
These_DT rights_NNS provide_VBP Merck_NNP with_IN safeguards_NNS over_IN the_DT activities_NNS of_IN the_DT partnership_NN and_CC place_NN some_DT limitations_NNS over_IN AstraZenecas_NNP discretion_NN to_TO operate_VB with_IN complete_JJ commercial_JJ freedom_NN ._.
The_DT restructuring_NN agreements_NNS provide_VBP for_IN the_DT following_VBG ongoing_JJ payment_NN and_CC termination_NN arrangements_NNS :_: Annual_JJ contingent_JJ payments_NNS Partial_NNP Redemption_NNP First_NNP Option_NN Second_JJ Option_NN In_IN addition_NN ,_, included_VBD in_IN the_DT assets_NNS and_CC liabilities_NNS covered_VBN by_IN the_DT restructuring_NN is_VBZ a_DT loan_NN note_NN receivable_NN by_IN AstraZeneca_NNP from_IN Merck_NNP with_IN a_DT face_NN value_NN of_IN $_$ 1.4_CD bn_NN ._.
Each_DT of_IN these_DT elements_NNS is_VBZ discussed_VBN in_IN further_JJ detail_NN below_IN ._.
Under_IN the_DT terms_NNS of_IN the_DT 1998_CD restructuring_NN ,_, the_DT merger_NN in_IN 1999_CD between_IN Astra_NNP and_CC Zeneca_NNP triggered_VBD two_CD one-time_JJ payments_NNS from_IN AstraZeneca_NNP to_TO Merck_NNP :_: a_DT Lump_NNP Sum_NNP Payment_NN of_IN $_$ 809m_CD ,_, which_WDT was_VBD charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ,_, as_IN a_DT result_NN of_IN which_WDT Merck_NNP relinquished_VBD any_DT claims_NNS to_TO Zeneca_NNP products_NNS :_: and_CC an_DT Advance_NNP Payment_NN of_IN $_$ 967m_CD ._.
This_DT Advance_NNP Payment_NN was_VBD calculated_VBN as_IN the_DT then_RB net_JJ present_JJ value_NN of_IN $_$ 2.8_CD bn_NN discounted_VBN from_IN 2008_CD to_TO the_DT date_NN of_IN payment_NN at_IN a_DT rate_NN of_IN 13_CD %_NN per_IN annum_NN and_CC causes_VBZ Merck_NNP to_TO relinquish_VB any_DT rights_NNS ,_, including_VBG contingent_JJ payments_NNS on_IN future_JJ sales_NNS ,_, to_TO Astra_NNP products_NNS with_IN no_DT existing_VBG or_CC pending_VBG US_NNP patents_NNS at_IN the_DT time_NN of_IN the_DT merger_NN ._.
As_IN the_DT Advance_NNP Payment_NN provides_VBZ AstraZeneca_NNP with_IN relief_NN from_IN future_JJ payments_NNS on_IN these_DT products_NNS and_CC relief_NN from_IN any_DT other_JJ potential_JJ obligations_NNS or_CC restrictions_NNS in_IN respect_NN of_IN these_DT products_NNS ,_, this_DT amount_NN has_VBZ been_VBN capitalized_VBN as_IN an_DT intangible_JJ asset_NN and_CC is_VBZ being_VBG amortised_VBN over_IN 20_CD years_NNS ._.
The_DT Advance_NNP Payment_NN is_VBZ subject_JJ to_TO a_DT true-up_NN in_IN 2008_CD ,_, as_IN discussed_VBN under_IN First_NNP Option_NN below_IN ._.
Annual_JJ contingent_JJ payments_NNS AstraZeneca_NNP makes_VBZ ongoing_JJ payments_NNS to_TO Merck_NNP based_VBN on_IN sales_NNS of_IN certain_JJ of_IN its_PRP$ products_NNS in_IN the_DT US_NNP the_DT contingent_JJ payments_NNS on_IN the_DT agreement_NN products_NNS ._.
As_IN a_DT result_NN of_IN the_DT 1999_CD merger_NN ,_, these_DT contingent_JJ payments_NNS excluding_VBG those_DT in_IN respect_NN of_IN Prilosec_NNP and_CC Nexium_NNP can_MD not_RB be_VB less_JJR than_IN annual_JJ minimum_NN sums_NNS between_IN 2002_CD and_CC 2007_CD ranging_VBG from_IN $_$ 125m_CD to_TO $_$ 225m_CD ._.
The_DT payments_NNS have_VBP exceeded_VBN the_DT minimum_JJ level_NN in_IN 2002_CD to_TO 2004_CD and_CC AstraZeneca_NNP has_VBZ no_DT reason_NN to_TO believe_VB that_IN the_DT annual_JJ payments_NNS in_IN the_DT future_NN will_MD fall_VB below_IN the_DT minimum_NN obligations_NNS ._.
Partial_JJ Redemption_NN In_IN 2008_CD ,_, there_EX will_MD be_VB a_DT partial_JJ redemption_NN of_IN Mercks_NNP limited_JJ partnership_NN interest_NN which_WDT will_MD end_VB Mercks_NNP interests_NNS including_VBG rights_NNS to_TO contingent_JJ payments_NNS in_IN respect_NN of_IN certain_JJ of_IN the_DT agreement_NN products_NNS by_IN distribution_NN to_TO Merck_NNP of_IN an_DT amount_NN calculated_VBN as_IN a_DT multiple_NN of_IN the_DT average_JJ annual_JJ contingent_JJ payments_NNS from_IN 2005_CD to_TO 2007_CD on_IN the_DT relevant_JJ products_NNS ,_, plus_CC $_$ 750m_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 110_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD First_JJ Option_NN In_IN 2008_CD ,_, a_DT calculation_NN will_MD be_VB made_VBN of_IN the_DT Appraised_NNP Value_NNP ,_, being_VBG the_DT net_JJ present_JJ value_NN of_IN the_DT future_JJ contingent_JJ payments_NNS in_IN respect_NN of_IN all_DT agreement_NN products_NNS not_RB covered_VBN by_IN the_DT Partial_NNP Redemption_NNP ,_, other_JJ than_IN Prilosec_NNP and_CC Nexium_NNP ._.
Payment_NN of_IN this_DT amount_NN to_TO Merck_NNP in_IN 2008_CD is_VBZ ,_, however_RB ,_, contingent_NN on_IN Mercks_NNP exercise_NN of_IN the_DT First_NNP Option_NN ._.
Exercise_NN of_IN the_DT First_NNP Option_NN will_MD require_VB AstraZeneca_NNP to_TO buy_VB out_RP Mercks_NNPS interest_NN in_IN these_DT products_NNS at_IN the_DT Appraised_NNP Value_NNP ._.
Should_MD Merck_NNP not_RB exercise_VB this_DT option_NN in_IN 2008_CD ,_, AstraZeneca_NNP may_MD exercise_VB it_PRP in_IN 2010_CD for_IN a_DT sum_NN equal_JJ to_TO the_DT 2008_CD Appraised_NNP Value_NNP ._.
If_IN neither_DT Merck_NNP nor_CC AstraZeneca_NNP exercise_VBP the_DT option_NN ,_, the_DT contingent_JJ payment_NN arrangements_NNS in_IN respect_NN of_IN these_DT agreement_NN products_NNS will_MD continue_VB as_RB will_MD other_JJ potential_JJ obligations_NNS and_CC restrictions_NNS in_IN respect_NN of_IN these_DT products_NNS and_CC the_DT Appraised_NNP Value_NNP will_MD not_RB be_VB paid_VBN ._.
In_IN addition_NN ,_, in_IN 2008_CD there_EX will_MD be_VB a_DT true-up_NN of_IN the_DT Advance_NNP Payment_NN ._.
The_DT calculation_NN of_IN this_DT will_MD be_VB based_VBN on_IN a_DT multiple_NN of_IN the_DT average_JJ annual_JJ contingent_JJ payments_NNS from_IN 2005_CD to_TO 2007_CD in_IN respect_NN of_IN all_PDT the_DT agreement_NN products_NNS with_IN the_DT exception_NN of_IN Prilosec_NNP and_CC Nexium_NNP subject_JJ to_TO a_DT minimum_NN of_IN $_$ 6.6_CD bn_NN ,_, plus_CC other_JJ defined_VBN amounts_NNS totalling_VBG $_$ 912m_CD ._.
It_PRP is_VBZ then_RB reduced_VBN by_IN the_DT Appraised_NNP Value_NNP whether_IN paid_VBN or_CC not_RB ,_, the_DT Partial_NNP Redemption_NNP and_CC the_DT Advance_NNP Payment_NN at_IN its_PRP$ undiscounted_JJ amount_NN of_IN $_$ 2.8_CD bn_NN to_TO determine_VB the_DT true-up_JJ amount_NN ._.
The_DT true-up_NN will_MD be_VB settled_VBN in_IN 2008_CD irrespective_RB of_IN whether_IN the_DT First_NNP Option_NN is_VBZ exercised_VBN and_CC this_DT could_MD result_VB in_IN a_DT further_JJ payment_NN by_IN AstraZeneca_NNP to_TO Merck_NNP or_CC a_DT payment_NN by_IN Merck_NNP to_TO AstraZeneca_NNP ._.
Should_MD Merck_NNP exercise_NN the_DT First_NNP Option_NN in_IN 2008_CD ,_, AstraZeneca_NNP will_MD make_VB payments_NNS in_IN respect_NN of_IN the_DT Partial_NNP Redemption_NNP ,_, the_DT First_NNP Option_NN and_CC the_DT true-up_JJ totalling_VBG a_DT minimum_NN of_IN $_$ 4.7_CD bn_NN ._.
If_IN AstraZeneca_NNP exercises_VBZ the_DT First_NNP Option_NN in_IN 2010_CD ,_, the_DT combined_VBN effect_NN will_MD involve_VB a_DT minimum_JJ aggregate_JJ amount_NN payable_JJ to_TO Merck_NNP in_IN 2008_CD and_CC 2010_CD of_IN the_DT same_JJ amount_NN ._.
Loan_NN Note_NN Receivable_NNP In_IN 2008_CD ,_, at_IN the_DT same_JJ time_NN as_IN the_DT settlement_NN of_IN the_DT Partial_NNP Redemption_NNP and_CC the_DT true-up_NN ,_, Merck_NNP will_MD settle_VB the_DT loan_NN note_NN receivable_NN by_IN paying_VBG AstraZeneca_NNP $_$ 1.4_CD bn_NN ._.
Second_JJ Option_NN A_DT Second_JJ Option_NN exists_VBZ whereby_WRB AstraZeneca_NNP has_VBZ the_DT option_NN to_TO re-purchase_VB Mercks_NNP interests_NNS in_IN Prilosec_NNP and_CC Nexium_NNP in_IN the_DT US_NNP ._.
This_DT option_NN is_VBZ exercisable_JJ by_IN AstraZeneca_NNP two_CD years_NNS after_IN the_DT exercise_NN of_IN the_DT First_NNP Option_NN ,_, whether_IN the_DT First_NNP Option_NN is_VBZ exercised_VBN in_IN either_DT 2008_CD or_CC 2010_CD ._.
Exercise_NN of_IN the_DT Second_JJ Option_NN by_IN AstraZeneca_NNP at_IN a_DT later_JJ date_NN is_VBZ also_RB provided_VBN for_IN in_IN 2017_CD or_CC if_IN combined_VBN annual_JJ sales_NNS of_IN the_DT two_CD products_NNS fall_VBP below_IN a_DT minimum_JJ amount_NN provided_VBN ,_, in_IN each_DT case_NN ,_, that_IN the_DT First_NNP Option_NN has_VBZ been_VBN exercised_VBN ._.
The_DT exercise_NN price_NN for_IN the_DT Second_JJ Option_NN is_VBZ the_DT fair_JJ value_NN of_IN these_DT product_NN rights_NNS as_IN determined_VBN at_IN the_DT time_NN of_IN exercise_NN ._.
If_IN the_DT Second_JJ Option_NN is_VBZ exercised_VBN ,_, Merck_NNP will_MD relinquish_VB all_DT its_PRP$ interests_NNS including_VBG rights_NNS to_TO contingent_JJ payments_NNS in_IN AstraZeneca_NNP products_NNS ._.
Accounting_NNP treatment_NN The_DT precise_JJ amount_NN of_IN settlements_NNS with_IN Merck_NNP under_IN the_DT Partial_NNP Redemption_NNP ,_, the_DT First_NNP Option_NN and_CC the_DT true-up_NN of_IN the_DT Advance_NNP Payment_NN can_MD not_RB be_VB determined_VBN at_IN this_DT time_NN ._.
The_DT Partial_NNP Redemption_NNP and_CC true-up_NN are_VBP calculated_VBN based_VBN ,_, in_IN part_NN ,_, on_IN trading_NN performance_NN between_IN 2005_CD and_CC 2007_CD ,_, and_CC payment_NN of_IN the_DT First_NNP Option_NN is_VBZ contingent_JJ upon_IN Merck_NNP or_CC AstraZeneca_NNP exercising_VBG the_DT First_NNP Option_NN ._.
If_IN Merck_NNP exercises_VBZ the_DT First_NNP Option_NN in_IN 2008_CD ,_, the_DT net_JJ minimum_NN payment_NN to_TO be_VB made_VBN to_TO Merck_NNP ,_, being_VBG the_DT combined_VBN payments_NNS of_IN $_$ 4.7_CD bn_NN less_JJR the_DT repayment_NN of_IN the_DT loan_NN note_NN of_IN $_$ 1.4_CD bn_NN ,_, would_MD be_VB $_$ 3.3_CD bn_NN ._.
In_IN accounting_NN for_IN the_DT Restructuring_NN in_IN 1998_CD ,_, the_DT loan_NN note_NN was_VBD included_VBN in_IN the_DT determination_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT assets_NNS and_CC liabilities_NNS to_TO be_VB acquired_VBN ._.
The_DT loan_NN note_NN was_VBD ascribed_VBN a_DT fair_JJ value_NN of_IN zero_CD on_IN acquisition_NN and_CC on_IN the_DT balance_NN sheet_NN because_IN it_PRP is_VBZ estimated_VBN that_IN the_DT net_JJ minimum_NN payment_NN of_IN $_$ 3.3_CD bn_NN equated_VBN to_TO the_DT fair_JJ value_NN of_IN the_DT trading_NN rights_NNS to_TO be_VB acquired_VBN under_IN the_DT Partial_NNP Redemption_NNP and_CC First_NNP Option_NN ._.
It_PRP is_VBZ considered_VBN that_IN the_DT payments_NNS described_VBN under_IN the_DT headings_NNS above_IN ,_, including_VBG the_DT Second_JJ Option_NN ,_, represent_VBP the_DT acquisition_NN of_IN future_JJ trading_NN rights_NNS which_WDT will_MD terminate_VB Mercks_NNP interests_NNS in_IN the_DT agreement_NN products_NNS including_VBG their_PRP$ rights_NNS to_TO contingent_JJ payments_NNS and_CC which_WDT will_MD provide_VB AstraZeneca_NNP with_IN unencumbered_JJ discretion_NN in_IN our_PRP$ operations_NNS in_IN the_DT US_NNP market_NN ._.
Mercks_NNP interests_NNS will_MD only_RB be_VB terminated_VBN as_IN and_CC when_WRB the_DT payments_NNS are_VBP made_VBN and_CC ,_, accordingly_RB ,_, the_DT acquisition_NN of_IN these_DT trading_NN rights_NNS will_MD only_RB be_VB reflected_VBN in_IN the_DT Financial_NNP Statements_NNP at_IN that_DT point_NN ._.
The_DT trading_NN rights_NNS will_MD be_VB accounted_VBN for_IN under_IN the_DT extant_JJ guidance_NN when_WRB the_DT payments_NNS are_VBP made_VBN ,_, with_IN allocations_NNS to_TO intangibles_NNS and_CC goodwill_NN ,_, as_IN appropriate_JJ ._.
As_IN noted_VBN ,_, the_DT calculation_NN of_IN the_DT purchase_NN price_NN of_IN the_DT trading_NN rights_NNS is_VBZ based_VBN partially_RB on_IN the_DT contingent_JJ payments_NNS made_VBN in_IN 2005_CD to_TO 2007_CD subject_JJ to_TO the_DT minimum_NN amount_NN and_CC is_VBZ likely_JJ to_TO be_VB substantially_RB driven_VBN by_IN the_DT sales_NNS of_IN Toprol-XL_NNP ,_, Pulmicort_NNP ,_, Rhinocort_NNP and_CC Atacand_NNP ._.
However_RB ,_, AstraZeneca_NNP anticipates_VBZ that_IN the_DT benefits_NNS that_WDT will_MD accrue_VB to_TO the_DT Company_NN from_IN these_DT payments_NNS will_MD begin_VB to_TO be_VB realized_VBN from_IN 2008_CD onwards_NNS based_VBN on_IN contributions_NNS from_IN those_DT products_NNS that_WDT have_VBP already_RB been_VBN launched_VBN for_IN example_NN ,_, Rhinocort_NNP and_CC Atacand_NNP ,_, those_DT that_WDT are_VBP due_JJ to_TO be_VB launched_VBN in_IN the_DT US_NNP in_IN particular_JJ ,_, Symbicort_NNP and_CC those_DT that_WDT are_VBP in_IN development_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 111_CD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD The_DT ongoing_JJ monitoring_NN of_IN the_DT projected_VBN payments_NNS to_TO Merck_NNP and_CC the_DT value_NN of_IN the_DT related_JJ trading_NN rights_NNS to_TO AstraZeneca_NNP takes_VBZ full_JJ account_NN of_IN changing_VBG business_NN circumstances_NNS and_CC the_DT range_NN of_IN possible_JJ outcomes_NNS to_TO ensure_VB that_IN the_DT payments_NNS to_TO be_VB made_VBN to_TO Merck_NNP are_VBP covered_VBN by_IN the_DT benefits_NNS expected_VBN to_TO be_VB realized_VBN by_IN the_DT Company_NN ._.
Should_MD the_DT monitoring_NN reveal_VBP that_IN these_DT payments_NNS exceed_VBP the_DT benefits_NNS expected_VBN to_TO be_VB realized_VBN ,_, a_DT provision_NN for_IN an_DT onerous_JJ contract_NN will_MD be_VB recognized_VBN ._.
The_DT annual_JJ contingent_JJ payments_NNS on_IN agreement_NN products_NNS are_VBP expensed_VBN as_IN incurred_VBN ._.
Environmental_JJ costs_NNS and_CC liabilities_NNS The_DT Groups_NNS expenditure_NN on_IN environmental_JJ protection_NN ,_, including_VBG both_DT capital_NN and_CC revenue_NN items_NNS ,_, relates_VBZ to_TO costs_NNS which_WDT are_VBP necessary_JJ for_IN meeting_VBG current_JJ good_JJ practice_NN standards_NNS and_CC legal_JJ and_CC regulatory_JJ requirements_NNS for_IN processes_NNS and_CC products_NNS ._.
They_PRP are_VBP an_DT integral_JJ part_NN of_IN normal_JJ ongoing_JJ expenditure_NN for_IN maintaining_VBG the_DT Groups_NNS R&D_NNP and_CC manufacturing_VBG capacity_NN and_CC product_NN ranges_NNS and_CC are_VBP not_RB separated_VBN from_IN overall_JJ operating_NN and_CC development_NN costs_NNS ._.
There_EX are_VBP no_DT known_VBN changes_NNS in_IN legal_JJ ,_, regulatory_JJ or_CC other_JJ requirements_NNS resulting_VBG in_IN material_NN changes_NNS to_TO the_DT levels_NNS of_IN expenditure_NN for_IN 2002_CD ,_, 2003_CD or_CC 2004_CD ._.
In_IN addition_NN to_TO expenditure_NN for_IN meeting_NN current_JJ and_CC foreseen_VBN environmental_JJ protection_NN requirements_NNS ,_, the_DT Group_NNP incurs_VBZ substantial_JJ costs_NNS in_IN investigating_VBG and_CC cleaning_VBG up_RP land_NN and_CC groundwater_NN contamination_NN ._.
In_IN particular_JJ ,_, AstraZeneca_NNP and_CC or_CC its_PRP$ affiliates_NNS have_VBP environmental_JJ liabilities_NNS at_IN some_DT currently_RB or_CC formerly_RB owned_VBN ,_, leased_VBN and_CC third_JJ party_NN sites_NNS ._.
In_IN the_DT US_NNP ,_, the_DT AstraZeneca_NNP affiliate_NN ,_, Zeneca_NNP Inc._NNP and_CC or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN as_IN potentially_RB responsible_JJ parties_NNS PRPs_NNS or_CC defendants_NNS at_IN approximately_RB 13_CD sites_NNS where_WRB Zeneca_NNP Inc._NNP is_VBZ likely_JJ to_TO incur_VB future_JJ investigation_NN ,_, remediation_NN or_CC operation_NN and_CC maintenance_NN costs_NNS under_IN federal_JJ or_CC state_NN ,_, statutory_JJ or_CC common_JJ law_NN environmental_JJ liability_NN allocations_NNS schemes_NNS ._.
Similarly_RB ,_, the_DT AstraZeneca_NNP affiliate_NN ,_, Stauffer_NNP Management_NNP Company_NNP LLC_NNP SMC_NNP ,_, which_WDT was_VBD established_VBN in_IN 1987_CD to_TO own_VB and_CC manage_VB certain_JJ assets_NNS of_IN Stauffer_NNP Chemical_NNP Company_NNP acquired_VBD that_DT year_NN ,_, and_CC or_CC its_PRP$ indemnitees_NNS ,_, have_VBP been_VBN named_VBN as_IN PRPs_NNS or_CC defendants_NNS at_IN approximately_RB 29_CD sites_NNS where_WRB SMC_NNP is_VBZ likely_JJ to_TO incur_VB future_JJ investigation_NN ,_, remediation_NN or_CC operation_NN and_CC maintenance_NN costs_NNS under_IN federal_JJ or_CC state_NN ,_, statutory_JJ or_CC common_JJ law_NN environmental_JJ liability_NN allocations_NNS schemes_NNS ._.
In_IN Europe_NNP and_CC other_JJ parts_NNS of_IN the_DT world_NN outside_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ likely_JJ to_TO incur_VB costs_NNS at_IN three_CD currently_RB owned_VBN sites_NNS and_CC has_VBZ given_VBN indemnities_NNS to_TO third_JJ parties_NNS in_IN respect_NN of_IN approximately_RB 45_CD other_JJ sites_NNS ._.
These_DT environmental_JJ liabilities_NNS arise_VBP almost_RB entirely_RB from_IN legacy_NN operations_NNS that_WDT are_VBP not_RB part_NN of_IN our_PRP$ current_JJ pharmaceuticals_NNS business_NN and_CC ,_, at_IN most_JJS of_IN these_DT sites_NNS ,_, remediation_NN ,_, where_WRB required_VBN ,_, is_VBZ either_RB completed_VBN or_CC nearing_VBG completion_NN ._.
In_IN the_DT aggregate_NN ,_, however_RB ,_, significant_JJ expenditure_NN on_IN clean_JJ up_RB and_CC monitoring_NN is_VBZ likely_JJ to_TO be_VB required_VBN ._.
AstraZeneca_NNP has_VBZ made_VBN provisions_NNS for_IN the_DT estimated_VBN costs_NNS of_IN future_JJ environmental_JJ investigation_NN ,_, remediation_NN and_CC operation_NN and_CC maintenance_NN activity_NN beyond_IN normal_JJ ongoing_JJ expenditure_NN for_IN maintaining_VBG the_DT Groups_NNS R&D_NNP and_CC manufacturing_VBG capacity_NN and_CC product_NN ranges_NNS where_WRB it_PRP is_VBZ probable_JJ that_IN such_JJ costs_NNS will_MD be_VB incurred_VBN and_CC can_MD be_VB estimated_VBN reliably_RB ._.
With_IN respect_NN to_TO such_JJ estimated_VBN ,_, future_JJ costs_NNS ,_, there_EX were_VBD provisions_NNS at_IN 31_CD December_NNP 2004_CD in_IN the_DT aggregate_NN of_IN approximately_RB $_$ 96m_CD ,_, of_IN which_WDT approximately_RB $_$ 86m_CD relates_VBZ to_TO the_DT US_NNP ._.
These_DT provisions_NNS do_VBP not_RB include_VB possible_JJ ,_, additional_JJ costs_NNS that_WDT are_VBP not_RB currently_RB probable_JJ ,_, nor_CC do_VB these_DT provisions_NNS include_VBP costs_NNS that_IN ,_, by_IN agreement_NN ,_, will_MD be_VB borne_VBN by_IN viable_JJ third_JJ party_NN indemnitors_NNS ._.
In_IN addition_NN ,_, these_DT provisions_NNS :_: 1_CD include_VBP ,_, where_WRB appropriate_JJ ,_, unasserted_JJ claims_NNS where_WRB future_JJ costs_NNS are_VBP nonetheless_RB probable_JJ at_IN owned_VBN sites_NNS ,_, for_IN example_NN :_: 2_CD are_VBP based_VBN ,_, where_WRB applicable_JJ ,_, on_IN liability_NN allocation_NN or_CC cost_NN sharing_NN agreements_NNS that_IN we_PRP believe_VBP are_VBP enforceable_JJ against_IN viable_JJ third_JJ parties_NNS :_: 3_CD reflect_VBP expected_VBN insurance_NN recoveries_NNS where_WRB an_DT insurer_NN has_VBZ agreed_VBN to_TO provide_VB an_DT indemnity_NN :_: and_CC 4_CD typically_RB cover_VBP a_DT time_NN period_NN of_IN five_CD years_NNS with_IN the_DT exception_NN of_IN operation_NN and_CC maintenance_NN activity_NN ,_, which_WDT can_MD last_VB for_IN decades_NNS ._.
AstraZeneca_NNP is_VBZ not_RB presently_RB aware_JJ of_IN any_DT circumstances_NNS or_CC uncertainties_NNS regarding_VBG the_DT viability_NN of_IN liable_JJ third_JJ parties_NNS ,_, indemnitors_NNS or_CC insurers_NNS that_WDT would_MD cause_VB these_DT provisions_NNS to_TO be_VB altered_VBN ._.
It_PRP is_VBZ possible_JJ that_IN the_DT Company_NN ,_, or_CC its_PRP$ affiliates_NNS ,_, could_MD incur_VB future_JJ environmental_JJ costs_NNS beyond_IN the_DT extent_NN of_IN our_PRP$ current_JJ provisions_NNS ._.
The_DT extent_NN of_IN such_JJ possible_JJ ,_, additional_JJ costs_NNS is_VBZ inherently_RB difficult_JJ to_TO estimate_VB due_JJ to_TO a_DT number_NN of_IN factors_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO :_: 1_CD the_DT nature_NN and_CC extent_NN of_IN claims_NNS that_WDT may_MD be_VB asserted_VBN in_IN the_DT future_NN :_: 2_CD whether_IN the_DT Company_NN or_CC any_DT of_IN its_PRP$ affiliates_NNS has_VBZ or_CC will_MD have_VB any_DT legal_JJ obligation_NN with_IN respect_NN to_TO asserted_VBD or_CC unasserted_JJ claims_NNS :_: 3_CD the_DT type_NN of_IN remedial_JJ action_NN ,_, if_IN any_DT ,_, that_WDT may_MD be_VB selected_VBN at_IN sites_NNS where_WRB the_DT remedy_NN is_VBZ presently_RB not_RB known_VBN :_: 4_LS the_DT potential_NN for_IN recoveries_NNS from_IN or_CC allocation_NN of_IN liability_NN to_TO third_JJ parties_NNS :_: and_CC 5_CD the_DT length_NN of_IN time_NN that_IN the_DT environmental_JJ investigation_NN ,_, remediation_NN and_CC liability_NN allocation_NN process_NN can_MD take_VB ._.
Notwithstanding_IN and_CC subject_JJ to_TO the_DT foregoing_NN ,_, it_PRP is_VBZ estimated_VBN that_IN potential_JJ additional_JJ loss_NN ,_, for_IN future_JJ environmental_JJ investigation_NN ,_, remediation_NN and_CC operation_NN and_CC maintenance_NN activity_NN above_IN and_CC beyond_IN our_PRP$ provisions_NNS ,_, could_MD be_VB ,_, in_IN the_DT aggregate_NN ,_, in_IN the_DT order_NN of_IN $_$ 20m_CD to_TO $_$ 40m_CD ._.
Legal_JJ proceedings_NNS AstraZeneca_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ proceedings_NNS considered_VBN typical_JJ to_TO its_PRP$ businesses_NNS ,_, including_VBG litigation_NN relating_VBG to_TO employment_NN ,_, product_NN liability_NN ,_, commercial_JJ disputes_NNS ,_, infringement_NN of_IN intellectual_JJ property_NN rights_NNS and_CC the_DT validity_NN of_IN certain_JJ patents_NNS ._.
The_DT more_JJR significant_JJ matters_NNS are_VBP discussed_VBN below_IN ._.
Crestor_NNP rosuvastatin_NN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP and_CC or_CC AstraZeneca_NNP LP_NNP in_IN the_DT US_NNP have_VBP been_VBN served_VBN with_IN two_CD individual_JJ lawsuits_NNS involving_VBG alleged_JJ injury_NN in_IN association_NN with_IN the_DT use_NN of_IN Crestor_NNP ._.
In_IN addition_NN ,_, a_DT motion_NN for_IN authorisation_NN to_TO institute_VB a_DT class_NN action_NN and_CC to_TO be_VB a_DT representative_NN was_VBD filed_VBN in_IN Quebec_NNP ,_, Canada_NNP against_IN AstraZeneca_NNP PLC_NNP and_CC AstraZeneca_NNP Canada_NNP Inc._NNP ._.
The_DT petitioner_NN claims_VBZ alleged_JJ injury_NN as_IN a_DT result_NN of_IN the_DT use_NN of_IN Crestor_NNP ._.
AstraZeneca_NNP is_VBZ vigorously_RB defending_VBG all_DT such_JJ claims_NNS and_CC lawsuits_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 112_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD Diprivan_NNP propofol_NN In_IN August_NNP 2002_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN ESI_NNP Lederle_NNP ,_, a_DT division_NN of_IN Wyeth_NNP ,_, informing_VBG AstraZeneca_NNP of_IN Wyeths_NNP intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Diprivan_NNP prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS covering_VBG the_DT current_JJ formulation_NN ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Wyeth_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
Through_IN a_DT series_NN of_IN transactions_NNS ,_, the_DT holder_NN of_IN the_DT relevant_JJ Abbreviated_NNP New_NNP Drug_NNP Application_NNP ANDA_NNP and_CC now_RB defendant_NN in_IN AstraZenecas_NNP suit_NN is_VBZ Mayne_NNP Pharma_NNP USA_NNP Inc._NNP formerly_RB called_VBD Faulding_NNP Pharmaceutical_NNP Co._NNP ._.
Mayne_NNP responded_VBD to_TO AstraZenecas_NNP complaint_NN and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ ,_, invalidity_NN and_CC unenforceability_NN ._.
Discovery_NNP and_CC claim_NN construction_NN took_VBD place_NN during_IN 2004_CD and_CC the_DT trial_NN is_VBZ expected_VBN to_TO commence_NN in_IN February_NNP 2005_CD ._.
AstraZeneca_NNP maintains_VBZ that_IN its_PRP$ patents_NNS are_VBP valid_JJ ,_, enforceable_JJ and_CC infringed_VBN by_IN Maynes_NNP propofol_NN product_NN ._.
If_IN the_DT court_NN finds_VBZ that_IN AstraZenecas_NNP patents_NNS are_VBP valid_JJ ,_, enforceable_JJ and_CC infringed_VBN by_IN Maynes_NNP propofol_NN product_NN ,_, AstraZeneca_NNP will_MD seek_VB an_DT injunction_NN preventing_VBG the_DT manufacture_NN ,_, use_NN ,_, sale_NN and_CC offering_NN for_IN sale_NN in_IN the_DT US_NNP of_IN Maynes_NNP propofol_NN product_NN ._.
Under_IN the_DT ANDA_NNP statute_NN ,_, the_DT FDA_NNP may_MD not_RB approve_VB Maynes_NNP propofol_NN product_NN before_IN February_NNP 2005_CD ._.
Exanta_NNP ximelagatran_NN On_IN or_CC about_IN 27_CD January_NNP 2005_CD ,_, a_DT putative_JJ class_NN action_NN was_VBD filed_VBN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP on_IN behalf_NN of_IN purchasers_NNS of_IN AstraZeneca_NNP publicly_RB traded_VBD securities_NNS during_IN the_DT period_NN 2_CD April_NNP 2003_CD to_TO 11_CD October_NNP 2004_CD against_IN AstraZeneca_NNP PLC_NNP ,_, Percy_NNP Barnevik_NNP ,_, Hkan_NNP Mogren_NNP ,_, Sir_NNP Tom_NNP McKillop_NNP and_CC Jonathan_NNP Symonds_NNPS ._.
The_DT lawsuit_NN asserts_VBZ claims_NNS under_IN sections_NNS 10_CD b_NN and_CC 20_CD a_DT of_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD and_CC SEC_NNP Rule_NNP 10b-5_JJ ,_, alleging_VBG that_IN the_DT defendants_NNS made_VBD false_JJ and_CC misleading_JJ statements_NNS regarding_VBG Exanta_NNP clinical_JJ trials_NNS and_CC the_DT status_NN of_IN the_DT New_NNP Drug_NNP Application_NNP for_IN Exanta_NNP in_IN the_DT US_NNP ._.
AstraZeneca_NNP denies_VBZ the_DT allegations_NNS and_CC will_MD vigorously_RB defend_VB the_DT action_NN ._.
Iressa_NNP gefitinib_NN In_IN 2004_CD ,_, two_CD claims_NNS were_VBD filed_VBN against_IN AstraZeneca_NNP KK_NNP in_IN Japan_NNP ,_, in_IN the_DT Osaka_NNP and_CC Tokyo_NNP District_NNP Courts_NNPS respectively_RB ._.
In_IN each_DT claim_NN ,_, it_PRP is_VBZ alleged_VBN that_IN Iressa_NNP caused_VBD a_DT fatal_JJ incidence_NN of_IN interstitial_JJ lung_NN disease_NN ILD_NNP in_IN a_DT Japanese_JJ patient_NN ._.
AstraZeneca_NNP KK_NNP ,_, following_VBG consultation_NN with_IN external_JJ legal_JJ advisers_NNS ,_, believes_VBZ the_DT claims_NNS are_VBP without_IN merit_NN and_CC is_VBZ defending_VBG both_DT cases_NNS ._.
ILD_NNP is_VBZ a_DT known_JJ complication_NN of_IN lung_NN disease_NN ,_, including_VBG advanced_JJ lung_NN cancer_NN ,_, regardless_RB of_IN treatment_NN ._.
Losec_NNP Prilosec_NNP omeprazole_NN In_IN March_NNP 2000_CD ,_, the_DT German_NNP Federal_NNP Patent_NNP Court_NNP declared_VBD that_IN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN was_VBD invalid_JJ ._.
AstraZeneca_NNP appealed_VBD the_DT decision_NN to_TO the_DT German_JJ Supreme_NNP Court_NNP ._.
As_IN a_DT consequence_NN ,_, all_DT pending_VBG infringement_NN actions_NNS in_IN Germany_NNP were_VBD stayed_VBN awaiting_VBG the_DT outcome_NN of_IN the_DT appeal_NN ._.
At_IN the_DT time_NN ,_, AstraZeneca_NNP obtained_VBD an_DT interlocutory_JJ injunction_NN against_IN ratiopharm_JJ GmbH_NNP based_VBN on_IN the_DT formulation_NN patent_NN ._.
In_IN March_NNP 2004_CD ,_, the_DT German_NNP Supreme_NNP Court_NNP heard_VBD AstraZenecas_NNP appeal_NN and_CC the_DT court_NN confirmed_VBD the_DT decision_NN of_IN the_DT German_JJ Federal_NNP Patent_NNP Court_NNP declaring_VBG the_DT patent_NN invalid_JJ ._.
AstraZeneca_NNP has_VBZ sought_VBN leave_NN to_TO appeal_VB this_DT decision_NN to_TO the_DT German_JJ Constitutional_NNP Court_NNP ._.
Following_VBG the_DT German_JJ Supreme_NNP Court_NNP decision_NN ,_, ratiopharm_NN GmbH_NNP was_VBD seeking_VBG damages_NNS from_IN AstraZeneca_NNP for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunction_NN obtained_VBN by_IN AstraZeneca_NNP against_IN ratiopharm_NN ._.
In_IN January_NNP 2005_CD ,_, the_DT matter_NN was_VBD settled_VBN on_IN terms_NNS which_WDT do_VBP not_RB have_VB a_DT material_NN effect_NN on_IN AstraZenecas_NNP financial_JJ position_NN ._.
In_IN June_NNP and_CC July_NNP 2004_CD ,_, AstraZeneca_NNP applied_VBD in_IN France_NNP for_IN injunctions_NNS based_VBN on_IN its_PRP$ omeprazole_NN formulation_NN patent_NN against_IN six_CD companies_NNS for_IN marketing_NN generic_JJ omeprazole_NN ._.
In_IN August_NNP 2004_CD ,_, the_DT applications_NNS were_VBD rejected_VBN at_IN first_JJ instance_NN ._.
AstraZeneca_NNP has_VBZ appealed_VBN this_DT decision_NN ._.
A_DT hearing_NN on_IN the_DT appeal_NN is_VBZ scheduled_VBN for_IN February_NNP 2005_CD ._.
In_IN May_NNP 2004_CD ,_, AstraZeneca_NNP also_RB started_VBD legal_JJ proceedings_NNS against_IN the_DT same_JJ companies_NNS for_IN infringement_NN of_IN its_PRP$ omeprazole_NN formulation_NN patent_NN in_IN France_NNP ._.
These_DT proceedings_NNS have_VBP been_VBN consolidated_VBN with_IN a_DT case_NN challenging_VBG the_DT validity_NN of_IN the_DT patent_NN ,_, brought_VBN by_IN one_CD of_IN the_DT companies_NNS against_IN AstraZeneca_NNP ._.
No_DT date_NN has_VBZ yet_RB been_VBN set_VBN for_IN a_DT hearing_NN ._.
In_IN 2001_CD ,_, AstraZeneca_NNP filed_VBD suit_NN in_IN the_DT US_NNP against_IN Andrx_NNP Pharmaceuticals_NNP ,_, Inc._NNP for_IN infringement_NN of_IN a_DT patent_NN directed_VBD to_TO a_DT process_NN for_IN making_VBG an_DT omeprazole_NN formulation_NN the_DT 281_CD patent_NN ._.
Andrx_NNP filed_VBD counterclaims_NNS of_IN non-infringement_NN ,_, invalidity_NN and_CC unenforceability_NN for_IN inequitable_JJ conduct_NN during_IN prosecution_NN of_IN the_DT 281_CD patent_NN ._.
Andrx_NNP also_RB asserted_VBD that_IN the_DT 281_CD patent_NN as_RB well_RB as_IN two_CD formulation_NN patents_NNS ,_, the_DT 505_CD and_CC 230_CD patents_NNS ,_, were_VBD unenforceable_JJ for_IN alleged_JJ litigation_NN misconduct_NN by_IN AstraZeneca_NNP ._.
Both_DT parties_NNS sought_VBD attorneys_NNS fees_NNS ._.
In_IN May_NNP 2004_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ruled_VBD that_IN the_DT 281_CD patent_NN was_VBD infringed_VBN ,_, but_CC also_RB ruled_VBD that_IN the_DT 281_CD patent_NN was_VBD invalid_JJ ._.
The_DT court_NN dismissed_VBD Andrxs_NNP litigation_NN misconduct_NN and_CC other_JJ counterclaims_NNS and_CC affirmative_JJ defences_NNS ,_, leaving_VBG intact_JJ the_DT courts_NNS October_NNP 2002_CD decision_NN finding_VBG the_DT 230_CD and_CC 505_CD patents_NNS not_RB invalid_JJ and_CC infringed_VBN by_IN Andrx_NNP ._.
The_DT October_NNP 2002_CD decision_NN was_VBD affirmed_VBN in_IN all_DT respects_NNS on_IN appeal_NN in_IN December_NNP 2003_CD ._.
The_DT court_NN entered_VBD final_JJ judgement_NN regarding_VBG the_DT 281_CD patent_NN in_IN July_NNP 2004_CD ,_, after_IN determining_VBG to_TO stay_VB the_DT attorneys_NNS fees_NNS claims_NNS pending_VBG any_DT appeals_NNS ._.
Andrx_NNP has_VBZ appealed_VBN the_DT judgement_NN and_CC AstraZeneca_NNP has_VBZ cross-appealed_VBN ._.
In_IN April_NNP 2001_CD ,_, Andrx_NNP filed_VBD a_DT case_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN AstraZeneca_NNP ,_, Merck_NNP &_CC Co._NNP ._.
Inc._NNP and_CC the_DT US_NNP Food_NNP and_CC Drug_NNP Administration_NNP ,_, alleging_VBG that_IN the_DT listing_NN of_IN certain_JJ patents_NNS in_IN the_DT FDAs_NNP Orange_NNP Book_NNP was_VBD improper_JJ and_CC constituted_VBD violations_NNS of_IN certain_JJ provisions_NNS of_IN the_DT Sherman_NNP Act_NNP ,_, the_DT US_NNP federal_JJ anti-trust_JJ legislation_NN ,_, and_CC a_DT state_NN statute_NN analogous_JJ to_TO the_DT federal_JJ anti-trust_JJ laws_NNS ._.
Andrx_NNP sought_VBD injunctive_JJ relief_NN compelling_JJ the_DT parties_NNS to_TO fide-list_JJ omeprazole-related_JJ patents_NNS it_PRP claimed_VBD were_VBN improperly_RB listed_VBN in_IN the_DT Orange_NNP Book_NNP and_CC prohibiting_VBG the_DT defendants_NNS from_IN using_VBG patents_NNS to_TO delay_VB the_DT effective_JJ date_NN of_IN the_DT FDAs_NNS approval_NN of_IN Andrxs_NNP Abbreviated_NNP New_NNP Drug_NNP Application_NNP for_IN omeprazole_NN ._.
AstraZeneca_NNP and_CC Merck_NNP filed_VBD motions_NNS to_TO dismiss_VB the_DT case_NN and_CC Andrx_NNP filed_VBD a_DT motion_NN for_IN summary_NN judgement_NN ._.
The_DT case_NN was_VBD stayed_VBN by_IN the_DT court_NN in_IN 2001_CD and_CC then_RB administratively_RB dismissed_VBN in_IN 2002_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 113_CD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD During_IN 2000_CD and_CC 2001_CD ,_, AstraZeneca_NNP had_VBD filed_VBN suits_NNS against_IN Lek_NNP Pharmaceutical_NNP and_CC Chemical_NNP Company_NNP d._NNP d._NN and_CC Lek_NNP Services_NNPS USA_NNP ,_, Inc._NNP ._.
Impax_NNP Laboratories_NNPS Inc._NNP ._.
Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP ._.
Mylan_NNP Pharmaceuticals_NNP Inc._NNP ._.
Apotex_NNP Corp_NNP ,_, Apotex_NNP ,_, Inc._NNP and_CC Torpharm_NNP ,_, Inc._NNP and_CC Zenith_NNP Goldline_NNP Pharmaceuticals_NNP ,_, Inc._NNP now_RB known_VBN as_IN Ivax_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
These_DT suits_NNS followed_VBD the_DT filing_NN of_IN Abbreviated_NNP New_NNP Drug_NNP Applications_NNS by_IN these_DT companies_NNS with_IN the_DT FDA_NNP concerning_VBG the_DT companies_NNS intention_NN to_TO market_NN generic_JJ omeprazole_NN products_NNS in_IN the_DT US_NNP ._.
The_DT basis_NN for_IN the_DT proceedings_NNS is_VBZ that_IN the_DT actions_NNS of_IN all_PDT the_DT companies_NNS infringe_VBP the_DT 505_CD and_CC 230_CD formulation_NN patents_NNS relating_VBG to_TO omeprazole_NN ._.
The_DT cases_NNS are_VBP proceeding_VBG under_IN the_DT US_NNP Hatch-Waxman_NNP legislation_NN ._.
The_DT case_NN against_IN Ivax_NNP was_VBD dismissed_VBN without_IN prejudice_NN shortly_RB after_IN it_PRP was_VBD filed_VBN ,_, after_IN Ivax_NNP withdrew_VBD its_PRP$ application_NN to_TO market_NN generic_JJ omeprazole_NN ._.
During_IN 2003_CD ,_, after_IN Mylan_NNP commenced_VBD commercial_JJ sale_NN of_IN its_PRP$ product_NN ,_, AstraZeneca_NNP filed_VBD suit_NN against_IN Laboratorios_NNP Esteve_NNP ,_, SA_NNP and_CC Esteve_NNP Quimica_NNP ,_, SA_NNP ,_, manufacturers_NNS of_IN the_DT omeprazole_JJ product_NN to_TO be_VB distributed_VBN in_IN the_DT US_NNP by_IN Mylan_NNP ._.
In_IN 2003_CD and_CC 2004_CD ,_, Lek_NNP ,_, Apotex_NNP and_CC Impax_NNP all_DT began_VBD commercial_JJ sales_NNS of_IN their_PRP$ generic_JJ omeprazole_NN products_NNS ._.
AstraZeneca_NNP has_VBZ added_VBN claims_NNS for_IN damages_NNS against_IN each_DT of_IN the_DT selling_NN defendants_NNS ._.
Anti-trust_NN and_CC non-infringement_JJ counterclaims_NNS have_VBP been_VBN filed_VBN by_IN Andrx_NNP ,_, Apotex_NNP Torpharm_NNP ,_, Impax_NNP ,_, Eon_NNP and_CC Lek_NNP ._.
All_DT defendants_NNS but_CC Lek_NNP have_VBP also_RB raised_VBN invalidity_NN and_CC unenforceability_NN counterclaims_NNS ._.
The_DT anti-trust_JJ counterclaims_NNS ,_, as_RB well_RB as_IN AstraZenecas_NNP claims_NNS for_IN damages_NNS ,_, have_VBP been_VBN stayed_VBN pending_VBG resolution_NN of_IN the_DT patent_NN liability_NN issues_NNS ._.
The_DT cases_NNS have_VBP been_VBN consolidated_VBN for_IN discovery_NN before_IN ,_, or_CC are_VBP directly_RB assigned_VBN to_TO ,_, Judge_NNP Jones_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP ._.
All_DT discovery_NN is_VBZ expected_VBN to_TO be_VB completed_VBN in_IN February_NNP 2005_CD ._.
In_IN July_NNP 2004_CD ,_, Lek_NNP filed_VBD a_DT motion_NN for_IN summary_NN judgement_NN of_IN non-infringement_JJ ,_, which_WDT is_VBZ pending_VBG ._.
Briefing_NN of_IN any_DT remaining_VBG motion_NN for_IN summary_NN judgement_NN is_VBZ scheduled_VBN to_TO be_VB completed_VBN by_IN April_NNP 2005_CD ._.
No_DT trial_NN date_NN has_VBZ been_VBN set_VBN ._.
During_IN 2000_CD ,_, AstraZeneca_NNP was_VBD granted_VBN interlocutory_JJ injunctions_NNS based_VBN on_IN certain_JJ of_IN AstraZenecas_NNP omeprazole_NN patents_NNS against_IN the_DT generic_JJ company_NN ,_, Scandinavian_NNP AB_NNP Scand_NNP Pharm_NNP ,_, in_IN Denmark_NNP and_CC Norway_NNP ._.
In_IN October_NNP 2001_CD ,_, Oslo_NNP City_NNP Court_NNP in_IN Norway_NNP found_VBD that_IN Scand_NNP Pharm_NNP had_VBD infringed_VBN AstraZenecas_NNP formulation_NN patent_NN for_IN omeprazole_NN ._.
At_IN the_DT same_JJ time_NN ,_, the_DT court_NN declared_VBD AstraZenecas_NNP formulation_NN patent_NN valid_JJ ._.
In_IN November_NNP 2004_CD ,_, these_DT findings_NNS were_VBD upheld_VBN by_IN the_DT Appeal_NNP Court_NNP ._.
As_IN a_DT result_NN of_IN the_DT Norwegian_JJ case_NN ,_, Scand_NNP Pharm_NNP can_MD not_RB sell_VB its_PRP$ omeprazole_JJ product_NN in_IN Norway_NNP ._.
Furthermore_RB ,_, it_PRP is_VBZ also_RB prevented_VBN from_IN selling_VBG its_PRP$ omeprazole_JJ product_NN in_IN Denmark_NNP pending_VBG the_DT outcome_NN of_IN the_DT main_JJ action_NN in_IN the_DT Danish_JJ case_NN ._.
If_IN the_DT final_JJ decisions_NNS in_IN these_DT cases_NNS are_VBP against_IN AstraZeneca_NNP ,_, Scand_NNP Pharm_NNP may_MD claim_VB damages_NNS for_IN lost_VBN sales_NNS due_JJ to_TO the_DT interlocutory_JJ injunctions_NNS ._.
During_IN 2003_CD and_CC 2004_CD ,_, AstraZeneca_NNP was_VBD denied_VBN interlocutory_JJ injunctions_NNS based_VBN on_IN certain_JJ of_IN its_PRP$ omeprazole_NN patents_NNS against_IN Novartis_NNP Sverige_NNP AB_NNP and_CC ratiopharm_JJ AB_NNP in_IN Sweden_NNP and_CC Novartis_NNP Finland_NNP Oy_NNP and_CC ratiopharm_JJ Oy_NNP in_IN Finland_NNP ._.
An_DT interlocutory_JJ injunction_NN against_IN Biochemie_NNP Novartis_NNP Healthcare_NNP A_NNP S_NNP was_VBD granted_VBN in_IN Denmark_NNP during_IN 2003_CD ,_, based_VBN on_IN AstraZenecas_NNP omeprazole_NN formulation_NN patent_NN ._.
Also_RB during_IN 2003_CD ,_, the_DT District_NNP Court_NNP in_IN Norway_NNP found_VBD that_IN the_DT generic_JJ omeprazole_NN product_NN marketed_VBN by_IN ratiopharm_JJ AS_NNP did_VBD not_RB infringe_VB AstraZenecas_NNP omeprazole_JJ formulation_NN patent_NN ._.
In_IN December_NNP 2004_CD ,_, an_DT interlocutary_JJ injunction_NN against_IN Nomeco_NNP A_NNP S_NNP ,_, a_DT Danish_JJ distributor_NN of_IN a_DT generic_JJ omeprazole_NN product_NN from_IN ratiopharm_NN ,_, was_VBD granted_VBN in_IN Denmark_NNP based_VBN on_IN AstraZenecas_NNP omeprazole_NN formulation_NN patent_NN ._.
AstraZeneca_NNP has_VBZ been_VBN and_CC continues_VBZ to_TO be_VB involved_VBN in_IN numerous_JJ proceedings_NNS in_IN Canada_NNP involving_VBG Genpharm_NNP ,_, Reddy_NNP Cheminor_NNP ,_, Rhoxalpharma_NNP and_CC Apotex_NNP ._.
These_DT cases_NNS relate_VBP to_TO omeprazole_VB capsules_NNS or_CC omeprazole_NN magnesium_NN tablets_NNS and_CC involve_VB various_JJ patents_NNS ._.
AstraZeneca_NNP could_MD potentially_RB be_VB liable_JJ for_IN damages_NNS in_IN some_DT cases_NNS ._.
However_RB ,_, there_EX are_VBP no_DT financial_JJ claims_NNS currently_RB being_VBG made_VBN against_IN AstraZeneca_NNP in_IN Canada_NNP in_IN any_DT litigation_NN in_IN respect_NN of_IN omeprazole_NN capsules_NNS or_CC omeprazole_NN magnesium_NN tablets_NNS ._.
Apotex_NNP launched_VBD a_DT generic_JJ omeprazole_NN capsule_NN product_NN in_IN Canada_NNP in_IN January_NNP 2004_CD ._.
Following_VBG this_DT launch_NN ,_, AstraZeneca_NNP commenced_VBD judicial_JJ review_NN proceedings_NNS seeking_VBG to_TO quash_VB Apotexs_NNP Notice_NNP of_IN Compliance_NNP marketing_NN approval_NN ._.
In_IN September_NNP 2004_CD ,_, the_DT case_NN was_VBD decided_VBN against_IN AstraZeneca_NNP ._.
AstraZenecas_NNP appeal_NN of_IN the_DT September_NNP 2004_CD decision_NN is_VBZ scheduled_VBN for_IN February_NNP 2005_CD ._.
AstraZeneca_NNP sued_VBD Apotex_NNP in_IN July_NNP 2004_CD alleging_VBG infringement_NN of_IN its_PRP$ formulation_NN patents_NNS by_IN Apotexs_NNP omeprazole_NN capsules_NNS ._.
In_IN February_NNP 2000_CD ,_, the_DT European_JJ Commission_NNP commenced_VBD an_DT investigation_NN relating_VBG to_TO certain_JJ omeprazole_NN intellectual_JJ property_NN rights_NNS ,_, and_CC associated_VBN regulatory_JJ and_CC patent_NN infringement_NN litigation_NN ._.
The_DT investigation_NN is_VBZ pursuant_JJ to_TO Article_NNP 82_CD of_IN the_DT EC_NNP Treaty_NNP ,_, which_WDT prohibits_VBZ an_DT abuse_NN of_IN a_DT dominant_JJ position_NN ._.
The_DT investigation_NN was_VBD precipitated_VBN by_IN a_DT complaint_NN by_IN a_DT party_NN to_TO a_DT number_NN of_IN patent_NN and_CC other_JJ proceedings_NNS involving_VBG AstraZeneca_NNP ._.
AstraZeneca_NNP has_VBZ ,_, in_IN accordance_NN with_IN its_PRP$ corporate_JJ policy_NN ,_, co-operated_JJ with_IN the_DT Commission_NNP ._.
In_IN July_NNP 2003_CD ,_, the_DT Commission_NNP served_VBD a_DT Statement_NN of_IN Objections_NNS on_IN AstraZeneca_NNP ,_, referring_VBG to_TO alleged_VBN infringements_NNS regarding_VBG the_DT obtaining_VBG of_IN supplementary_JJ protection_NN certificates_NNS for_IN omeprazole_NN in_IN certain_JJ European_JJ countries_NNS :_: and_CC regarding_VBG AstraZenecas_NNP replacement_NN of_IN omeprazole_NN capsules_NNS by_IN omeprazole_NN MUPS_NNP tablets_NNS and_CC withdrawal_NN of_IN capsule_NN marketing_NN authorisations_NNS in_IN three_CD European_JJ countries_NNS ._.
AstraZeneca_NNP replied_VBD fully_RB to_TO the_DT Commission_NNP ,_, explaining_VBG why_WRB its_PRP$ actions_NNS were_VBD in_IN AstraZenecas_NNP view_NN lawful_JJ ._.
An_DT oral_JJ hearing_NN took_VBD place_NN in_IN February_NNP 2004_CD ._.
If_IN ,_, ultimately_RB ,_, and_CC subject_JJ to_TO any_DT appeals_NNS to_TO the_DT Court_NNP of_IN First_NNP Instance_NNP and_CC the_DT European_NNP Court_NNP of_IN Justice_NNP it_PRP is_VBZ held_VBN that_IN Article_NNP 82_CD has_VBZ been_VBN infringed_VBN ,_, then_RB there_EX may_MD be_VB a_DT liability_NN to_TO fines_NNS and_CC or_CC other_JJ measures_NNS which_WDT can_MD be_VB imposed_VBN by_IN the_DT Commission_NNP ._.
There_EX could_MD also_RB be_VB liability_NN for_IN alleged_JJ losses_NNS incurred_VBN by_IN aggrieved_JJ third_JJ parties_NNS ._.
It_PRP is_VBZ not_RB possible_JJ ,_, at_IN the_DT present_JJ time_NN ,_, to_TO quantify_VB any_DT such_JJ liabilities_NNS as_IN no_DT Decision_NN has_VBZ been_VBN issued_VBN by_IN the_DT Commission_NNP ,_, no_DT fines_NNS have_VBP to_TO date_NN been_VBN imposed_VBN and_CC no_DT claims_NNS for_IN damages_NNS have_VBP been_VBN received_VBN ._.
Moreover_RB ,_, bearing_VBG in_IN mind_NN the_DT timescales_NNS of_IN proceedings_NNS ,_, including_VBG appeals_NNS ,_, there_EX may_MD well_RB be_VB a_DT considerable_JJ period_NN before_IN any_DT such_JJ liabilities_NNS are_VBP finally_RB established_VBN even_RB if_IN ,_, which_WDT is_VBZ denied_VBN ,_, any_DT such_JJ liabilities_NNS exist_VBP ._.
Nexium_NNP esomeprazole_NN AstraZeneca_NNP entities_NNS have_VBP been_VBN sued_VBN in_IN state_NN courts_NNS in_IN the_DT US_NNP in_IN purported_JJ representative_NN and_CC class_NN actions_NNS involving_VBG the_DT marketing_NN of_IN Nexium_NNP esomeprazole_NN ._.
These_DT actions_NNS generally_RB allege_VBP that_IN AstraZenecas_NNP promotion_NN and_CC advertising_NN of_IN Nexium_NNP to_TO physicians_NNS and_CC consumers_NNS is_VBZ unfair_JJ ,_, unlawful_JJ and_CC deceptive_JJ conduct_NN ,_, particularly_RB as_IN the_DT promotion_NN relates_VBZ to_TO comparisons_NNS of_IN Nexium_NNP with_IN Prilosec_NNP ._.
They_PRP also_RB allege_VBP that_IN AstraZenecas_NNP conduct_NN relating_VBG to_TO the_DT pricing_NN of_IN Nexium_NNP was_VBD unfair_JJ ,_, unlawful_JJ and_CC deceptive_JJ ._.
The_DT plaintiffs_NNS allege_VBP claims_NNS under_IN various_JJ state_NN consumer_NN protection_NN ,_, unfair_JJ practices_NNS and_CC false_JJ advertising_NN laws_NNS ._.
The_DT plaintiffs_NNS in_IN these_DT cases_NNS seek_VBP remedies_NNS that_WDT include_VBP restitution_NN ,_, disgorgement_NN of_IN profits_NNS ,_, damages_NNS ,_, punitive_JJ damages_NNS ,_, injunctive_JJ relief_NN ,_, attorneys_NNS fees_NNS and_CC costs_NNS of_IN suit_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 114_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD In_IN October_NNP 2004_CD ,_, the_DT first_JJ action_NN was_VBD brought_VBN in_IN the_DT Superior_NNP Court_NNP of_IN the_DT State_NN of_IN California_NNP for_IN the_DT County_NNP of_IN Los_NNP Angeles_NNP by_IN the_DT AFL-CIO_NNP ,_, two_CD unincorporated_JJ associations_NNS and_CC an_DT individual_NN on_IN behalf_NN of_IN themselves_PRP ,_, the_DT general_JJ public_NN and_CC a_DT class_NN of_IN California_NNP consumers_NNS ,_, third_JJ party_NN payers_NNS ,_, cash_NN payers_NNS and_CC those_DT making_VBG co-pay_NN ._.
A_DT second_JJ action_NN has_VBZ been_VBN filed_VBN in_IN the_DT same_JJ court_NN on_IN behalf_NN of_IN a_DT similar_JJ putative_JJ class_NN of_IN consumers_NNS ._.
Actions_NNS making_VBG similar_JJ allegations_NNS were_VBD filed_VBN on_IN behalf_NN of_IN a_DT putative_JJ class_NN of_IN consumers_NNS in_IN the_DT Circuit_NNP Court_NNP of_IN Searcy_NNP County_NNP ,_, Arkansas_NNP and_CC on_IN behalf_NN of_IN a_DT putative_JJ class_NN of_IN third_JJ party_NN payers_NNS in_IN the_DT Superior_NNP Court_NNP of_IN the_DT State_NN of_IN Delaware_NNP in_IN and_CC for_IN New_NNP Castle_NNP County_NNP ._.
In_IN addition_NN ,_, in_IN December_NNP 2004_CD ,_, AstraZeneca_NNP received_VBD a_DT pre-litigation_JJ demand_NN from_IN claimants_NNS in_IN Massachusetts_NNP who_WP allege_VBP similar_JJ claims_NNS under_IN Massachusetts_NNP law_NN on_IN behalf_NN of_IN themselves_PRP and_CC a_DT proposed_VBN class_NN of_IN purchasers_NNS of_IN Nexium_NNP in_IN Massachusetts_NNP ._.
AstraZeneca_NNP denies_VBZ the_DT allegations_NNS and_CC is_VBZ vigorously_RB defending_VBG each_DT of_IN these_DT actions_NNS ._.
In_IN October_NNP 2004_CD ,_, AstraZeneca_NNP LP_NNP filed_VBD suit_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP seeking_VBG declaratory_JJ judgement_NN that_IN its_PRP$ Better_NNP is_VBZ Better_RBR campaign_NN for_IN Nexium_NNP is_VBZ not_RB false_JJ or_CC misleading_JJ advertising_NN in_IN violation_NN of_IN section_NN 43_CD a_DT of_IN the_DT Lanham_NNP Act_NNP ,_, a_DT federal_JJ statute_NN governing_VBG false_JJ advertising_NN claims_NNS ._.
The_DT action_NN was_VBD taken_VBN in_IN response_NN to_TO a_DT letter_NN from_IN TAP_NNP Pharmaceuticals_NNP ,_, Inc._NNP demanding_VBG that_IN AstraZeneca_NNP immediately_RB withdraw_VB the_DT television_NN commercial_NN and_CC other_JJ components_NNS of_IN the_DT direct-to-consumer_NN advertising_NN campaign_NN for_IN Nexium_NNP on_IN the_DT basis_NN that_IN they_PRP allegedly_RB constitute_VBP violations_NNS of_IN the_DT statute_NN ._.
In_IN November_NNP 2004_CD ,_, TAP_NNP requested_VBD expedited_VBN consideration_NN of_IN the_DT case_NN by_IN filing_VBG a_DT motion_NN for_IN a_DT preliminary_JJ injunction_NN ._.
In_IN December_NNP 2004_CD ,_, the_DT court_NN held_VBD a_DT hearing_NN on_IN this_DT motion_NN and_CC denied_VBD the_DT request_NN for_IN a_DT preliminary_JJ injunction_NN ._.
A_DT trial_NN date_NN has_VBZ been_VBN scheduled_VBN for_IN April_NNP 2006_CD ._.
Nolvadex_NNP tamoxifen_NN AstraZeneca_NNP is_VBZ a_DT co-defendant_NN with_IN Barr_NNP Laboratories_NNPS ,_, Inc._NNP in_IN numerous_JJ purported_JJ class_NN actions_NNS filed_VBN in_IN federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP ._.
All_DT of_IN the_DT state_NN court_NN actions_NNS were_VBD removed_VBN to_TO federal_JJ court_NN and_CC have_VBP been_VBN consolidated_JJ ,_, along_IN with_IN all_DT of_IN the_DT cases_NNS originally_RB filed_VBN in_IN federal_JJ court_NN ,_, in_IN a_DT federal_JJ multi-district_JJ litigation_NN proceeding_VBG pending_VBG in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP ._.
Some_DT of_IN the_DT cases_NNS were_VBD filed_VBN by_IN plaintiffs_NNS representing_VBG a_DT putative_JJ class_NN of_IN consumers_NNS who_WP purchased_VBD tamoxifen_NN ._.
The_DT other_JJ cases_NNS were_VBD filed_VBN on_IN behalf_NN of_IN a_DT putative_JJ class_NN of_IN third_JJ party_NN payers_NNS including_VBG health_NN maintenance_NN organizations_NNS ,_, insurers_NNS and_CC other_JJ managed_VBN care_NN providers_NNS and_CC health_NN plans_NNS that_WDT have_VBP reimbursed_VBN or_CC otherwise_RB paid_VBN for_IN prescriptions_NNS of_IN tamoxifen_NN ._.
The_DT plaintiffs_NNS allege_VBP that_IN they_PRP paid_VBD supra-competitive_JJ and_CC monopolistic_JJ prices_NNS for_IN tamoxifen_NN as_IN a_DT result_NN of_IN the_DT settlement_NN of_IN patent_NN litigation_NN between_IN Zeneca_NNP and_CC Barr_NNP in_IN 1993_CD ._.
The_DT plaintiffs_NNS seek_VBP injunctive_JJ relief_NN ,_, treble_JJ damages_NNS under_IN the_DT anti-trust_JJ laws_NNS ,_, disgorgement_NN and_CC restitution_NN ._.
In_IN April_NNP 2002_CD ,_, AstraZeneca_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT cases_NNS for_IN failure_NN to_TO state_VB a_DT cause_NN of_IN action_NN ._.
In_IN May_NNP 2003_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN New_NNP York_NNP granted_VBD AstraZenecas_NNP motion_NN to_TO dismiss_VB ._.
The_DT plaintiffs_NNS appealed_VBD the_DT decision_NN ._.
Oral_JJ arguments_NNS in_IN the_DT appeal_NN were_VBD heard_VBN by_IN the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Second_NNP Circuit_NNP in_IN July_NNP 2004_CD ._.
The_DT courts_NNS decision_NN is_VBZ awaited_VBN ._.
Plendil_NNP felodipine_NN In_IN August_NNP 2000_CD ,_, AstraZeneca_NNP LP_NNP received_VBD a_DT letter_NN from_IN Mutual_JJ Pharmaceutical_NNP Co._NNP ._.
Inc._NNP informing_VBG AstraZeneca_NNP of_IN Mutuals_NNP intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN AstraZenecas_NNP Plendil_NNP extended_VBD release_NN tablets_NNS prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patent_NN covering_VBG the_DT extended_JJ release_NN formulation_NN ._.
AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Mutual_JJ in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP ._.
Mutual_JJ responded_VBD and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ and_CC invalidity_NN ._.
In_IN March_NNP 2003_CD ,_, the_DT District_NNP Court_NNP granted_VBD summary_NN judgement_NN in_IN favor_NN of_IN AstraZeneca_NNP as_IN to_TO the_DT infringement_NN claim_NN ,_, holding_VBG that_IN Mutual_JJ infringed_VBN AstraZenecas_NNP formulation_NN patent_NN ._.
In_IN August_NNP 2003_CD ,_, the_DT District_NNP Court_NNP granted_VBD summary_NN judgement_NN in_IN favor_NN of_IN AstraZeneca_NNP as_IN to_TO the_DT validity_NN claim_NN ,_, holding_VBG that_IN AstraZenecas_NNP patent_NN is_VBZ valid_JJ ._.
Mutual_JJ then_RB filed_VBD a_DT notice_NN of_IN appeal_NN as_IN to_TO both_DT of_IN these_DT decisions_NNS to_TO the_DT US_NNP District_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
In_IN September_NNP 2004_CD ,_, the_DT Federal_NNP Circuit_NNP Court_NNP reversed_VBD the_DT ruling_NN by_IN the_DT District_NNP Court_NNP as_IN to_TO infringement_NN and_CC held_VBD that_IN Mutuals_NNP extended_VBD release_NN felodipine_NN tablets_NNS ,_, as_IN a_DT matter_NN of_IN law_NN ,_, do_VBP not_RB infringe_VB AstraZenecas_NNP formulation_NN patent_NN ._.
However_RB ,_, the_DT Federal_NNP Circuit_NNP Court_NNP upheld_VBD the_DT District_NNP Courts_NNPS decision_NN as_IN to_TO validity_NN ,_, ruling_VBG that_IN AstraZenecas_NNP formulation_NN patent_NN is_VBZ valid_JJ as_IN a_DT matter_NN of_IN law_NN ._.
In_IN April_NNP 2004_CD ,_, Zenith_NNP Goldline_NNP Pharmaceuticals_NNP ,_, Inc._NNP now_RB known_VBN as_IN Ivax_NNP Pharmaceuticals_NNP ,_, Inc._NNP filed_VBD a_DT motion_NN for_IN summary_NN judgement_NN on_IN the_DT issue_NN of_IN non-infringement_NN in_IN the_DT patent_NN infringement_NN action_NN pending_VBG between_IN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP and_CC Zenith_NNP Ivax_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP ._.
The_DT patent_NN infringement_NN action_NN against_IN Zenith_NNP Ivax_NNP ,_, which_WDT AstraZeneca_NNP filed_VBD in_IN July_NNP 2001_CD ,_, resulted_VBD from_IN a_DT May_NNP 2001_CD letter_NN to_TO AstraZeneca_NNP in_IN which_WDT Zenith_NNP Ivax_NNP declared_VBD its_PRP$ intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Plendil_NNP extended_VBD release_NN tablets_NNS prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patent_NN covering_VBG the_DT extended_JJ release_NN formulation_NN ._.
Zenith_NNP Ivax_NNP filed_VBD counterclaims_NNS in_IN the_DT litigation_NN alleging_VBG non-infringement_JJ ._.
In_IN August_NNP 2004_CD ,_, the_DT District_NNP Court_NNP issued_VBD an_DT order_NN dismissing_VBG this_DT action_NN ,_, without_IN prejudice_NN ,_, pending_VBG the_DT consummation_NN of_IN a_DT settlement_NN of_IN the_DT matter_NN and_CC granting_VBG the_DT parties_NNS the_DT right_NN ,_, upon_IN motion_NN and_CC good_JJ cause_NN shown_VBN ,_, to_TO re-open_VB the_DT legal_JJ action_NN if_IN the_DT settlement_NN were_VBD not_RB consummated_VBN within_IN 60_CD days_NNS of_IN the_DT date_NN of_IN the_DT order_NN ._.
The_DT parties_NNS jointly_RB proposed_VBD to_TO the_DT District_NNP Court_NNP that_IN the_DT 60_CD day_NN period_NN be_VB extended_VBN by_IN 30_CD days_NNS ._.
In_IN November_NNP 2004_CD ,_, the_DT District_NNP Court_NNP entered_VBD an_DT order_NN of_IN dismissal_NN reflecting_VBG the_DT parties_NNS agreement_NN that_WDT AstraZeneca_NNP dismiss_VB its_PRP$ claim_NN of_IN infringement_NN and_CC Ivax_NNP dismiss_VB its_PRP$ counterclaim_NN of_IN invalidity_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 115_CD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD Seroquel_NNP quetiapine_NN fumarate_NN AstraZeneca_NNP PLC_NNP and_CC AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP have_VBP been_VBN named_VBN as_IN defendants_NNS in_IN the_DT case_NN of_IN Susan_NNP Zehel-Miller_NNP et_FW al._FW ._.
v._CC AstraZenaca_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, AstraZenaca_NNP Pharmaceuticals_NNP ,_, LP_NNP -LRB-_-LRB- sic_JJ -RRB-_-RRB- ,_, a_DT putative_JJ class_NN action_NN suit_NN filed_VBN in_IN August_NNP 2003_CD in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Middle_NNP District_NNP of_IN Florida_NNP ._.
The_DT named_VBN plaintiffs_NNS are_VBP seeking_VBG damages_NNS and_CC injunctive_JJ relief_NN on_IN behalf_NN of_IN a_DT purported_JJ class_NN consisting_VBG of_IN all_DT persons_NNS in_IN the_DT United_NNP States_NNPS who_WP purchased_VBD and_CC or_CC used_VBN Seroquel_NNP ._.
Although_IN the_DT scope_NN of_IN the_DT allegations_NNS in_IN the_DT complaint_NN is_VBZ very_RB broad_JJ ,_, the_DT primary_JJ focus_NN appears_VBZ to_TO be_VB the_DT contention_NN that_WDT AstraZeneca_NNP failed_VBD to_TO provide_VB adequate_JJ warnings_NNS in_IN connection_NN with_IN an_DT alleged_JJ association_NN between_IN Seroquel_NNP and_CC the_DT onset_NN of_IN diabetes_NN ._.
In_IN August_NNP 2004_CD ,_, the_DT court_NN denied_VBD class_NN certification_NN in_IN this_DT matter_NN ._.
The_DT plaintiffs_NNS motion_NN to_TO the_DT Court_NNP of_IN Appeals_NNPS for_IN leave_NN to_TO pursue_VB an_DT interlocutory_JJ appeal_NN of_IN the_DT decision_NN was_VBD denied_VBN in_IN January_NNP 2005_CD ._.
AstraZeneca_NNP is_VBZ vigorously_RB defending_VBG the_DT claims_NNS of_IN the_DT two_CD remaining_VBG plaintiffs_NNS in_IN this_DT matter_NN ._.
Symbicort_NNP budesonide_NN formoterol_NN In_IN February_NNP 2004_CD ,_, Ivax_NNP Pharmaceuticals_NNP UK_NNP Limited_NNP initiated_VBD proceedings_NNS against_IN AstraZeneca_NNP AB_NNP claiming_VBG that_IN the_DT UK_NNP parts_NNS of_IN two_CD European_JJ patents_NNS related_VBN to_TO Symbicort_NNP were_VBD invalid_JJ ._.
In_IN May_NNP 2004_CD ,_, the_DT court_NN granted_VBD AstraZenecas_NNP application_NN for_IN a_DT stay_NN of_IN the_DT proceedings_NNS pending_VBG the_DT determination_NN of_IN parallel_JJ opposition_NN proceedings_NNS before_IN the_DT European_JJ Patent_NNP Office_NNP ._.
In_IN April_NNP 2004_CD ,_, Ivax_NNP initiated_VBD proceedings_NNS against_IN AstraZeneca_NNP AB_NNP in_IN relation_NN to_TO the_DT Republic_NNP of_IN Ireland_NNP claiming_VBG that_IN two_CD European_JJ patents_NNS related_VBN to_TO Symbicort_NNP were_VBD invalid_JJ ._.
In_IN October_NNP 2004_CD ,_, the_DT court_NN granted_VBD AstraZenecas_NNP application_NN for_IN a_DT stay_NN of_IN proceedings_NNS pending_VBG the_DT final_JJ decision_NN of_IN the_DT European_JJ Patent_NNP Office_NNP and_CC its_PRP$ Boards_NNS of_IN Appeal_NNP in_IN the_DT opposition_NN proceedings_NNS ._.
Toprol-XL_JJ metoprolol_NN succinate_VB In_IN May_NNP 2003_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN KV_NNP Pharmaceutical_NNP Company_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP in_IN response_NN to_TO KVs_NNP notification_NN of_IN its_PRP$ intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 200mg_JJ dose_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS covering_VBG the_DT substance_NN and_CC its_PRP$ formulation_NN ._.
In_IN response_NN to_TO later_RB similar_JJ notices_NNS from_IN KV_NNP related_VBN to_TO the_DT 100mg_JJ and_CC 50mg_JJ doses_NNS ,_, AstraZeneca_NNP filed_VBD further_JJ actions_NNS ._.
KV_NNP responded_VBD in_IN each_DT instance_NN and_CC filed_VBD counterclaims_NNS alleging_VBG non-infringement_JJ ,_, invalidity_NN and_CC unenforceability_NN of_IN the_DT listed_VBN patents_NNS ._.
In_IN February_NNP 2004_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Andrx_NNP Pharmaceuticals_NNP LLC_NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP in_IN response_NN to_TO Andrxs_NNP notification_NN of_IN its_PRP$ intention_NN to_TO market_VB a_DT generic_JJ version_NN of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 50mg_JJ dose_NN prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS ._.
In_IN response_NN to_TO two_CD later_JJ similar_JJ notices_NNS from_IN Andrx_NNP related_VBN to_TO the_DT 25mg_JJ ,_, 100mg_JJ and_CC 200mg_JJ doses_NNS ,_, AstraZeneca_NNP filed_VBD two_CD additional_JJ patent_NN infringement_NN actions_NNS in_IN the_DT same_JJ court_NN ._.
In_IN each_DT instance_NN ,_, Andrx_NNP claims_VBZ that_IN each_DT of_IN the_DT listed_VBN patents_NNS is_VBZ invalid_JJ ,_, not_RB infringed_VBN and_CC unenforceable_JJ ._.
In_IN April_NNP 2004_CD ,_, AstraZeneca_NNP filed_VBD a_DT patent_NN infringement_NN action_NN against_IN Eon_NNP Labs_NNPS Manufacturing_NNP Inc._NNP in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Delaware_NNP in_IN response_NN to_TO Eons_NNS notification_NN of_IN its_PRP$ intention_NN to_TO market_NN generic_JJ versions_NNS of_IN Toprol-XL_JJ tablets_NNS in_IN the_DT 25mg_JJ ,_, 50mg_JJ ,_, 100mg_JJ and_CC 200mg_JJ doses_NNS prior_RB to_TO the_DT expiration_NN of_IN AstraZenecas_NNP patents_NNS ._.
In_IN its_PRP$ response_NN ,_, Eon_NNP alleged_VBD that_IN each_DT of_IN the_DT listed_VBN patents_NNS is_VBZ invalid_JJ ,_, not_RB infringed_VBN and_CC unenforceable_JJ ._.
All_DT of_IN the_DT patent_NN litigation_NN relating_VBG to_TO Toprol-XL_NNP against_IN KV_NNP ,_, Andrx_NNP and_CC Eon_NNP has_VBZ been_VBN consolidated_VBN for_IN pre-trial_JJ discovery_NN purposes_NNS and_CC motion_NN practice_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT Eastern_NNP District_NNP of_IN Missouri_NNP ._.
The_DT defendants_NNS filed_VBD a_DT motion_NN for_IN summary_NN judgement_NN in_IN December_NNP 2004_CD alleging_VBG that_IN the_DT Toprol-XL_JJ patents_NNS are_VBP invalid_JJ due_JJ to_TO double_VB patenting_NN ._.
In_IN January_NNP 2005_CD AstraZeneca_NNP filed_VBD a_DT terminal_NN disclaimer_NN of_IN the_DT Toprol-XL_NNP patents-in-suit_NN over_IN one_CD of_IN the_DT other_JJ patents_NNS raised_VBN by_IN the_DT defendants_NNS ,_, which_WDT will_MD result_VB in_IN a_DT revision_NN of_IN the_DT expiration_NN date_NN of_IN the_DT Toprol-XL_NNP patents-in-suit_NN from_IN March_NNP 2008_CD to_TO September_NNP 2007_CD ._.
Discovery_NNP and_CC motion_NN practice_NN are_VBP expected_VBN to_TO be_VB active_JJ through_IN at_IN least_JJS the_DT first_JJ half_NN of_IN 2005_CD ._.
No_DT trial_NN date_NN has_VBZ been_VBN set_VBN in_IN the_DT consolidated_JJ proceedings_NNS ._.
Under_IN the_DT Abbreviated_NNP New_NNP Drug_NNP Application_NNP statute_NN ,_, the_DT FDA_NNP may_MD not_RB approve_VB KVs_NNP product_NN before_IN September_NNP 2005_CD ,_, Andrxs_NNP product_NN before_IN June_NNP 2006_CD or_CC Eons_NNS product_NN before_IN August_NNP 2006_CD ,_, unless_IN there_EX is_VBZ an_DT earlier_JJR adverse_JJ court_NN decision_NN ._.
AstraZeneca_NNP maintains_VBZ that_IN its_PRP$ patents_NNS are_VBP valid_JJ ,_, enforceable_JJ and_CC infringed_VBN by_IN these_DT KV_NNP ,_, Andrx_NNP and_CC Eon_NNP products_NNS ._.
Zestril_NNP lisinopril_NN In_IN 1996_CD ,_, two_CD of_IN AstraZenecas_NNP predecessor_NN companies_NNS ,_, Zeneca_NNP Limited_NNP and_CC Zeneca_NNP Pharma_NNP Inc._NNP as_IN licensees_NNS ,_, and_CC Merck_NNP &_CC Co._NNP ._.
Inc._NNP and_CC Merck_NNP Frosst_NNP Canada_NNP Inc._NNP commenced_VBD a_DT patent_NN infringement_NN action_NN in_IN the_DT Federal_NNP Court_NNP of_IN Canada_NNP against_IN Apotex_NNP Inc._NNP alleging_VBG infringement_NN of_IN Mercks_NNP lisinopril_NN patent_NN ._.
Apotex_NNP has_VBZ sold_VBN and_CC continues_VBZ to_TO sell_VB a_DT generic_JJ version_NN of_IN AstraZenecas_NNP Zestril_NNP and_CC Mercks_NNP Prinivil_NNP tablets_NNS ._.
Apotex_NNP has_VBZ admitted_VBN infringement_NN but_CC has_VBZ raised_VBN positive_JJ defences_NNS to_TO infringement_NN ,_, including_VBG that_IN it_PRP acquired_VBD certain_JJ quantities_NNS of_IN lisinopril_NN prior_RB to_TO issuance_NN of_IN the_DT patent_NN and_CC that_IN certain_JJ quantities_NNS were_VBD licensed_VBN under_IN a_DT compulsory_JJ licence_NN ._.
Apotex_NNP has_VBZ also_RB alleged_VBN invalidity_NN of_IN the_DT patent_NN ._.
The_DT trial_NN is_VBZ scheduled_VBN for_IN January_NNP 2006_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 116_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD Average_JJ wholesale_JJ price_NN class_NN action_NN litigation_NN In_IN January_NNP 2002_CD ,_, AstraZeneca_NNP was_VBD named_VBN as_IN a_DT defendant_NN along_IN with_IN 24_CD other_JJ pharmaceutical_JJ manufacturers_NNS in_IN a_DT class_NN action_NN suit_NN ,_, in_IN Massachusetts_NNP ,_, brought_VBD on_RP behalf_NN of_IN a_DT putative_JJ class_NN of_IN plaintiffs_NNS alleged_VBN to_TO have_VB overpaid_VBN for_IN prescription_NN drugs_NNS as_IN a_DT result_NN of_IN inflated_JJ wholesale_JJ list_NN prices_NNS ._.
The_DT suit_NN seeks_VBZ to_TO recover_VB unspecified_JJ damages_NNS ._.
AstraZeneca_NNP has_VBZ also_RB been_VBN named_VBN as_IN a_DT co-defendant_NN with_IN various_JJ other_JJ pharmaceutical_JJ manufacturers_NNS in_IN similar_JJ suits_NNS filed_VBN in_IN nine_CD other_JJ states_NNS ._.
Most_JJS of_IN these_DT suits_NNS have_VBP been_VBN consolidated_VBN with_IN the_DT Massachusetts_NNP action_NN for_IN pre-trial_JJ purposes_NNS pursuant_JJ to_TO federal_JJ multi-district_JJ litigation_NN procedures_NNS ._.
The_DT court_NN has_VBZ issued_VBN a_DT scheduling_NN order_NN setting_VBG out_RP a_DT briefing_NN schedule_NN for_IN class_NN certification_NN and_CC summary_NN judgement_NN motions_NNS ._.
That_DT order_NN groups_NNS five_CD of_IN the_DT pharmaceutical_JJ manufacturer_NN codefendants_NNS ,_, including_VBG AstraZeneca_NNP ,_, into_IN a_DT group_NN called_VBD the_DT Fast_NNP Track_NNP defendants_NNS ._.
The_DT court_NN has_VBZ scheduled_VBN a_DT hearing_NN on_IN the_DT plaintiffs_NNS motion_NN for_IN class_NN certification_NN relating_VBG to_TO the_DT Fast_NNP Track_NNP defendants_NNS for_IN February_NNP 2005_CD ._.
A_DT hearing_NN on_IN the_DT Fast_NNP Track_NNP motions_NNS for_IN summary_NN judgement_NN is_VBZ scheduled_VBN for_IN June_NNP 2005_CD ._.
In_IN addition_NN to_TO the_DT consolidated_JJ proceedings_NNS in_IN Massachusetts_NNP ,_, additional_JJ suits_NNS are_VBP proceeding_VBG independently_RB in_IN four_CD states_NNS ._.
These_DT include_VBP separate_JJ suits_NNS brought_VBN by_IN the_DT Commonwealth_NNP of_IN Pennsylvania_NNP ,_, the_DT Commonwealth_NNP of_IN Kentucky_NNP and_CC the_DT State_NN of_IN Wisconsin_NNP to_TO recover_VB alleged_JJ damages_NNS on_IN behalf_NN of_IN those_DT states_NNS and_CC their_PRP$ residents_NNS ,_, as_RB well_RB as_IN a_DT class_NN action_NN brought_VBN by_IN an_DT individual_JJ plaintiff_NN in_IN Arizona_NNP on_IN behalf_NN of_IN individuals_NNS and_CC entities_NNS in_IN that_DT state_NN ._.
AstraZeneca_NNP believes_VBZ that_IN it_PRP has_VBZ meritorious_JJ defences_NNS to_TO all_DT of_IN these_DT claims_NNS ._.
Retail_JJ pharmacies_NNS drug_NN purchasers_NNS actions_NNS Since_IN October_NNP 1993_CD ,_, several_JJ thousand_CD retail_JJ pharmacies_NNS and_CC certain_JJ retail_JJ drug_NN purchasers_NNS have_VBP commenced_VBN purported_JJ class_NN actions_NNS and_CC individual_JJ actions_NNS in_IN various_JJ federal_JJ and_CC state_NN courts_NNS throughout_IN the_DT US_NNP alleging_VBG that_IN ,_, with_IN respect_NN to_TO brand_NN name_NN prescription_NN drugs_NNS ,_, manufacturers_NNS and_CC wholesalers_NNS engaged_VBN in_IN discriminatory_JJ pricing_NN practices_NNS and_CC or_CC discriminatory_JJ discounting_NN and_CC rebate_NN practices_NNS ,_, and_CC or_CC conspired_VBN with_IN one_CD another_DT to_TO fix_VB prices_NNS and_CC artificially_RB maintain_VBP high_JJ prices_NNS to_TO the_DT plaintiffs_NNS in_IN restraint_NN of_IN trade_NN and_CC commerce_NN ._.
More_JJR than_IN 20_CD brand_NN name_NN prescription_NN drug_NN manufacturers_NNS and_CC eight_CD wholesalers_NNS have_VBP been_VBN named_VBN defendants_NNS in_IN some_DT or_CC all_DT of_IN these_DT suits_NNS ._.
In_IN November_NNP 2004_CD ,_, AstraZeneca_NNP settled_VBD the_DT single_JJ remaining_VBG retail_JJ case_NN pending_VBG against_IN it_PRP in_IN the_DT Northern_NNP District_NNP of_IN Illinois_NNP ._.
Consequently_RB ,_, all_DT of_IN these_DT cases_NNS against_IN AstraZeneca_NNP have_VBP now_RB been_VBN settled_VBN or_CC dismissed_VBN ._.
Additional_JJ government_NN investigations_NNS into_IN drug_NN marketing_NN practices_NNS As_IN is_VBZ true_JJ for_IN most_JJS ,_, if_IN not_RB all_DT ,_, major_JJ prescription_NN pharmaceutical_JJ companies_NNS operating_VBG in_IN the_DT US_NNP ,_, AstraZeneca_NNP is_VBZ currently_RB involved_VBN in_IN multiple_JJ additional_JJ US_NNP federal_JJ and_CC state_NN criminal_JJ and_CC civil_JJ investigations_NNS into_IN drug_NN marketing_NN and_CC pricing_NN practices_NNS ._.
Five_CD of_IN these_DT investigations_NNS are_VBP being_VBG handled_VBN by_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Boston_NNP ._.
One_CD involves_VBZ a_DT request_NN for_IN production_NN of_IN documents_NNS relating_VBG to_TO the_DT sale_NN and_CC promotion_NN of_IN Prilosec_NNP to_TO the_DT New_NNP England_NNP Medical_NNP Center_NNP in_IN Boston_NNP ._.
A_DT second_JJ subpoena_NN from_IN the_DT same_JJ office_NN requests_NNS documents_NNS relating_VBG to_TO the_DT sale_NN and_CC marketing_NN of_IN products_NNS to_TO an_DT individual_JJ physician_NN in_IN Worcester_NNP ,_, Massachusetts_NNP and_CC certain_JJ physicians_NNS and_CC entities_NNS affiliated_VBN with_IN that_DT physician_NN ._.
A_DT third_JJ subpoena_NN from_IN that_DT office_NN seeks_VBZ documents_NNS relating_VBG to_TO speaker_NN programs_NNS involving_VBG healthcare_NN professionals_NNS at_IN three_CD regional_JJ healthcare_NN entities_NNS in_IN the_DT Boston_NNP area_NN ._.
A_DT fourth_JJ subpoena_NN requests_NNS documents_NNS relating_VBG to_TO interactions_NNS with_IN physicians_NNS at_IN a_DT large_JJ ,_, regional_JJ clinic_NN and_CC affiliated_JJ entities_NNS in_IN north_JJ eastern_JJ Massachusetts_NNP ._.
The_DT fifth_JJ subpoena_NN from_IN the_DT Boston_NNP US_NNP Attorneys_NNP Office_NNP relates_VBZ to_TO the_DT marketing_NN and_CC sale_NN of_IN three_CD products_NNS Zestril_NNP ,_, Naropin_NNP and_CC Cefotan_NNP to_TO a_DT leading_VBG provider_NN of_IN pharmacy_NN services_NNS to_TO long_JJ term_NN care_NN facilities_NNS ._.
AstraZeneca_NNP has_VBZ received_VBN a_DT subpoena_NN from_IN the_DT Massachusetts_NNP Attorney_NNP Generals_NNP Office_NNP seeking_VBG documents_NNS relating_VBG to_TO the_DT sale_NN and_CC promotion_NN of_IN five_CD products_NNS Prilosec_NNP ,_, Seroquel_NNP ,_, Rhinocort_NNP Aqua_NNP ,_, Toprol-XL_NNP and_CC Zestril_NNP within_IN Massachusetts_NNP ._.
In_IN October_NNP 2004_CD ,_, AstraZeneca_NNP received_VBD a_DT subpoena_NN from_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Philadelphia_NNP principally_RB seeking_VBG documents_NNS relating_VBG to_TO the_DT formulary_JJ status_NN of_IN AstraZeneca_NNP drugs_NNS at_IN a_DT regional_JJ health_NN maintenance_NN organization_NN and_CC a_DT national_JJ pharmacy_NN benefits_NNS manager_NN ._.
Most_RBS recently_RB ,_, AstraZeneca_NNP ,_, along_IN with_IN 12_CD other_JJ pharmaceutical_JJ manufacturers_NNS ,_, was_VBD served_VBN with_IN a_DT subpoena_NN from_IN the_DT US_NNP Attorneys_NNP Office_NNP in_IN Philadelphia_NNP seeking_VBG documents_NNS in_IN connection_NN with_IN the_DT governments_NNS pending_VBG civil_JJ litigation_NN against_IN Medco_NNP Health_NNP Systems_NNPS ._.
That_DT subpoena_NN seeks_VBZ documents_NNS relating_VBG to_TO contracts_NNS ,_, programs_NNS ,_, grants_NNS or_CC payments_NNS to_TO Medco_NNP ._.
AstraZeneca_NNP is_VBZ co-operating_JJ fully_RB with_IN all_DT of_IN these_DT investigations_NNS ._.
It_PRP is_VBZ not_RB possible_JJ to_TO predict_VB the_DT outcome_NN of_IN any_DT of_IN these_DT investigations_NNS ,_, which_WDT could_MD include_VB the_DT payment_NN of_IN damages_NNS and_CC the_DT imposition_NN of_IN fines_NNS ,_, penalties_NNS and_CC administrative_JJ remedies_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 117_CD 30_CD Assets_NNPS pledged_VBD ,_, commitments_NNS and_CC contingent_JJ liabilities_NNS continued_VBD Drug_NN importation_NN anti-trust_JJ litigation_NN In_IN May_NNP 2004_CD ,_, plaintiffs_NNS in_IN a_DT purported_JJ class_NN action_NN filed_VBD complaints_NNS in_IN the_DT US_NNP District_NNP Court_NNP for_IN Minnesota_NNP and_CC for_IN New_NNP Jersey_NNP ,_, alleging_VBG that_IN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP and_CC eight_CD other_JJ pharmaceutical_JJ manufacturer_NN defendants_NNS conspired_VBD to_TO prevent_VB American_JJ consumers_NNS from_IN purchasing_VBG prescription_NN drugs_NNS from_IN Canada_NNP ,_, depriving_VBG consumers_NNS of_IN the_DT ability_NN to_TO purchase_VB drugs_NNS at_IN competitive_JJ prices_NNS ._.
The_DT New_NNP Jersey_NNP case_NN was_VBD voluntarily_RB dismissed_VBN in_IN July_NNP 2004_CD and_CC only_RB the_DT Minnesota_NNP proceedings_NNS remain_VBP pending_VBG ._.
The_DT plaintiffs_NNS seek_VBP injunctive_JJ relief_NN ,_, restitution_NN and_CC other_JJ remedies_NNS ._.
The_DT defendants_NNS in_IN the_DT Minnesota_NNP action_NN filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT case_NN for_IN failure_NN to_TO state_VB a_DT cause_NN of_IN action_NN ._.
Oral_JJ argument_NN on_IN the_DT motion_NN to_TO dismiss_VB was_VBD heard_VBN in_IN January_NNP 2005_CD ._.
A_DT decision_NN on_IN the_DT motion_NN is_VBZ awaited_VBN ._.
In_IN August_NNP 2004_CD ,_, Californian_NN retail_JJ pharmacy_NN plaintiffs_NNS filed_VBD an_DT action_NN in_IN the_DT Superior_NNP Court_NNP of_IN California_NNP making_VBG similar_JJ allegations_NNS ._.
As_IN in_IN the_DT Minnesota_NNP action_NN ,_, the_DT defendants_NNS in_IN this_DT action_NN have_VBP moved_VBN to_TO dismiss_VB the_DT case_NN for_IN failure_NN to_TO state_VB a_DT cause_NN of_IN action_NN ._.
It_PRP is_VBZ expected_VBN that_IN oral_JJ argument_NN on_IN the_DT motion_NN will_MD be_VB held_VBN in_IN early_JJ 2005_CD ._.
AstraZeneca_NNP denies_VBZ the_DT material_NN allegations_NNS of_IN both_DT the_DT Minnesota_NNP and_CC California_NNP actions_NNS and_CC is_VBZ vigorously_RB defending_VBG these_DT matters_NNS ._.
StarLink_NNP AstraZeneca_NNP Insurance_NNP Company_NNP Limited_NNP AZIC_NNP has_VBZ commenced_VBN arbitration_NN proceedings_NNS in_IN the_DT UK_NNP against_IN insurers_NNS in_IN respect_NN of_IN amounts_NNS paid_VBN by_IN Garst_NNP Seed_NN Company_NN of_IN the_DT US_NNP in_IN settlement_NN of_IN claims_NNS arising_VBG in_IN the_DT US_NNP from_IN Garsts_NNPS sale_NN of_IN StarLink_NNP ,_, a_DT genetically_RB engineered_VBN corn_NN seed_NN ._.
AstraZenecas_NNP interest_NN in_IN Garst_NNP was_VBD through_IN AstraZenecas_NNP 50_CD %_NN ownership_NN of_IN Advanta_NNP BV_NNP ,_, the_DT sale_NN of_IN which_WDT to_TO Syngenta_NNP was_VBD announced_VBN in_IN May_NNP 2004_CD and_CC completed_VBN in_IN September_NNP 2004_CD ._.
AZICs_NNS claim_VBP against_IN the_DT insurers_NNS will_MD not_RB be_VB affected_VBN by_IN the_DT disposal_NN of_IN AstraZenecas_NNP interest_NN in_IN Advanta_NNP BV_NNP ._.
In_IN April_NNP 2004_CD ,_, Comprehensive_NNP Cancer_NNP Centers_NNPS ,_, Inc._NNP ._.
CCC_NNP ,_, a_DT subsidiary_NN of_IN Salick_NNP Health_NNP Care_NNP ,_, Inc._NNP received_VBD a_DT subpoena_NN from_IN the_DT US_NNP Department_NNP of_IN Justice_NNP seeking_VBG ,_, among_IN other_JJ items_NNS ,_, medical_JJ records_NNS and_CC related_VBN documentation_NN for_IN services_NNS provided_VBN to_TO patients_NNS at_IN the_DT Comprehensive_NNP Cancer_NNP Center_NNP at_IN Desert_NNP Regional_NNP Medical_NNP Center_NNP in_IN Palm_NNP Springs_NNP ,_, California_NNP ._.
The_DT Center_NNP is_VBZ managed_VBN by_IN CCC_NNP ,_, which_WDT is_VBZ co-operating_JJ fully_RB with_IN the_DT document_NN request_NN ._.
Taxation_NNP Where_WRB tax_NN exposures_NNS can_MD be_VB quantified_VBN ,_, a_DT provision_NN is_VBZ made_VBN based_VBN on_IN best_JJS estimates_NNS and_CC managements_NNS judgement_NN ._.
Details_NNS of_IN the_DT material_NN tax_NN exposures_NNS are_VBP as_IN follows_VBZ :_: AstraZeneca_NNP has_VBZ made_VBN certain_JJ double_JJ taxation_NN relief_NN claims_NNS in_IN accordance_NN with_IN its_PRP$ understanding_NN of_IN existing_VBG law_NN ._.
We_PRP understand_VBP that_IN other_JJ taxpayers_NNS have_VBP recently_RB been_VBN denied_VBN credit_NN for_IN foreign_JJ taxes_NNS in_IN similar_JJ claims_NNS ._.
The_DT estimated_VBN tax_NN exposure_NN provided_VBN for_IN in_IN respect_NN of_IN the_DT issue_NN is_VBZ $_$ 197m_CD ,_, although_IN the_DT potential_JJ additional_JJ losses_NNS above_IN and_CC beyond_IN the_DT amount_NN provided_VBN is_VBZ estimated_VBN to_TO be_VB up_RB $_$ 130m_CD :_: however_RB ,_, management_NN believes_VBZ that_IN it_PRP is_VBZ unlikely_JJ that_IN these_DT additional_JJ losses_NNS will_MD arise_VB ._.
AstraZeneca_NNP expects_VBZ a_DT definitive_JJ ruling_NN or_CC clarification_NN of_IN law_NN on_IN the_DT availability_NN of_IN credit_NN for_IN foreign_JJ taxes_NNS in_IN the_DT next_JJ 12_CD months_NNS ._.
Until_IN these_DT cases_NNS are_VBP resolved_VBN either_RB in_IN court_NN or_CC through_IN clarification_NN of_IN existing_VBG law_NN ,_, there_EX is_VBZ some_DT risk_NN that_IN credits_NNS may_MD not_RB be_VB allowed_VBN ,_, giving_VBG rise_NN to_TO effective_JJ double_JJ taxation_NN ._.
In_IN this_DT event_NN ,_, the_DT Company_NN will_MD seek_VB relief_NN under_IN the_DT relevant_JJ double_JJ tax_NN treaty_NN ._.
AstraZeneca_NNP faces_VBZ a_DT number_NN of_IN transfer_NN pricing_NN audits_NN in_IN jurisdictions_NNS around_IN the_DT world_NN ._.
The_DT issues_NNS under_IN audit_NN are_VBP often_RB complex_JJ and_CC can_MD require_VB many_JJ years_NNS to_TO resolve_VB ._.
Accruals_NNS for_IN tax_NN contingencies_NNS require_VBP management_NN to_TO make_VB estimates_NNS and_CC judgements_NNS with_IN respect_NN to_TO the_DT ultimate_JJ outcome_NN of_IN a_DT tax_NN audit_NN ,_, and_CC actual_JJ results_NNS could_MD vary_VB from_IN these_DT estimates_NNS ._.
The_DT total_JJ accrual_NN included_VBD in_IN the_DT Financial_NNP Statements_NNP to_TO cover_VB the_DT worldwide_JJ exposure_NN to_TO transfer_VB pricing_NN audits_NN is_VBZ $_$ 400m_CD ._.
It_PRP is_VBZ not_RB possible_JJ to_TO estimate_VB any_DT additional_JJ exposure_NN that_WDT may_MD arise_VB or_CC the_DT timing_NN of_IN tax_NN cash_NN flows_VBZ in_IN relation_NN to_TO each_DT outcome_NN ._.
Included_VBN in_IN the_DT provision_NN is_VBZ an_DT amount_NN of_IN interest_NN of_IN $_$ 107m_CD ._.
Interest_NN is_VBZ accrued_VBN as_IN a_DT tax_NN expense_NN ._.
Of_IN the_DT remaining_VBG tax_NN exposures_NNS ,_, the_DT Company_NN does_VBZ not_RB expect_VB material_NN additional_JJ losses_NNS ._.
General_NNP With_IN respect_NN to_TO each_DT of_IN the_DT legal_JJ proceedings_NNS described_VBN above_IN ,_, other_JJ than_IN those_DT which_WDT have_VBP been_VBN disposed_VBN of_IN ,_, we_PRP are_VBP unable_JJ to_TO make_VB estimates_NNS of_IN the_DT loss_NN or_CC range_NN of_IN losses_NNS at_IN this_DT stage_NN ._.
We_PRP also_RB do_VBP not_RB believe_VB that_IN disclosure_NN of_IN the_DT amount_NN sought_VBN by_IN plaintiffs_NNS ,_, if_IN that_DT is_VBZ known_VBN ,_, would_MD be_VB meaningful_JJ with_IN respect_NN to_TO those_DT legal_JJ proceedings_NNS ._.
This_DT is_VBZ due_JJ to_TO a_DT number_NN of_IN factors_NNS including_VBG ,_, for_IN example_NN ,_, the_DT stage_NN of_IN the_DT proceedings_NNS in_IN many_JJ cases_NNS trial_NN dates_NNS have_VBP not_RB been_VBN set_VBN and_CC overall_JJ length_NN and_CC extent_NN of_IN legal_JJ discovery_NN :_: the_DT entitlement_NN of_IN the_DT parties_NNS to_TO an_DT action_NN to_TO appeal_VB a_DT decision_NN :_: clarity_NN as_IN to_TO theories_NNS of_IN liability_NN :_: damages_NNS and_CC governing_VBG law_NN :_: uncertainties_NNS in_IN timing_NN of_IN litigation_NN :_: and_CC the_DT possible_JJ need_NN for_IN further_JJ legal_JJ proceedings_NNS to_TO establish_VB the_DT appropriate_JJ amount_NN of_IN damages_NNS ,_, if_IN any_DT ._.
However_RB ,_, although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS or_CC investigations_NNS referred_VBD to_TO in_IN this_DT Note_NN 30_CD to_TO the_DT Financial_NNP Statements_NNP ,_, we_PRP do_VBP not_RB expect_VB them_PRP to_TO have_VB a_DT materially_RB adverse_JJ effect_NN on_IN our_PRP$ financial_JJ position_NN or_CC profitability_NN ._.
